| June 13, 2026 | Source | New source added: Detailed Results of a Clinical Study of Vladonix | — |
| Qi Supplements |
| June 13, 2026 | Source | New source added: Vladonix A-6 Thymus Natural Peptide Bioregulator (product page) | — |
| Vita-Stream |
| June 13, 2026 | Source | New source added: Thymus Extract — Uses, Dosage, Side Effects, Interactions | — |
| RxList / WebMD |
| June 13, 2026 | Source | New source added: Vladimir Khavinson — Wikipedia | — |
| June 13, 2026 | Source | New source added: Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials | — |
| Advances in Gerontology / Springer |
| June 13, 2026 | Source | New source added: Peptides of pineal gland and thymus prolong human life (NeL.edu abstract) | — |
| Neuro Endocrinology Letters |
| June 13, 2026 | Source | New source added: Peptides of pineal gland and thymus prolong human life | — |
| Neuro Endocrinology Letters |
| June 13, 2026 | Source | New source added: Clinical Study of the Biologically Active Peptide Bioregulator Vladonix | — |
| Antiaging Systems |
| June 13, 2026 | Source | New source added: Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus | — |
| Advances in Gerontology |
| June 13, 2026 | Source | New source added: The effect of vilon (Lys-Glu) on 1,2-dimethylhydrazine-induced neoplasia | — |
| Voprosy Onkologii |
| June 13, 2026 | Source | New source added: Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Effect of peptide Lys-Glu on interleukin-2 gene expression in lymphocytes | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice | — |
| Doklady Biological Sciences |
| June 13, 2026 | Source | New source added: Effect of vilon on biological age and lifespan in mice | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Urolithin A and nicotinamide riboside differentially regulate innate immune defenses and metabolism in human microglial cells | — |
| Frontiers in Aging Neuroscience |
| June 13, 2026 | Source | New source added: Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population | — |
| European Journal of Clinical Nutrition |
| June 13, 2026 | Source | New source added: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial | — |
| Nature Aging |
| June 13, 2026 | Source | New source added: Targeting aging with urolithin A in humans: A systematic review | — |
| Ageing Research Reviews |
| June 13, 2026 | Source | New source added: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults | — |
| Cell Reports Medicine |
| June 13, 2026 | Source | New source added: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial | — |
| JAMA Network Open |
| June 13, 2026 | Source | New source added: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans | — |
| Nature Metabolism |
| June 13, 2026 | Source | New source added: Thyreogen Peptide: Thyroid Bioregulator for Endocrine Support | — |
| June 13, 2026 | Source | New source added: Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials | — |
| Advances in Gerontology |
| June 13, 2026 | Source | New source added: Safety of Natural Peptide Bioregulators | — |
| June 13, 2026 | Source | New source added: Influence of Peptide Bioregulators on Morphology of Parenchymatous Organs | — |
| June 13, 2026 | Source | New source added: Thyreogen: The Thyroid Gland Peptide Bioregulator | — |
| June 13, 2026 | Source | New source added: Vladimir Khavinson — Wikipedia | — |
| June 13, 2026 | Source | New source added: Peptide bioregulation of aging: results and prospects | — |
| Biogerontology |
| June 13, 2026 | Source | New source added: Peptide bioregulator efficacy in the correction of reduced thyroid gland function in the residents of Magadan Region | — |
| Advances in Gerontology |
| June 13, 2026 | Source | New source added: Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NCT05984134) | — |
| June 13, 2026 | Source | New source added: Thymosin β4 inhibits TNF-α-induced NF-κB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK | — |
| PLoS ONE / PMC |
| June 13, 2026 | Source | New source added: Thymosin β4 Promotes Dermal Healing | — |
| Vitamins and Hormones / Elsevier |
| June 13, 2026 | Source | New source added: Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing | — |
| June 13, 2026 | Source | New source added: Progress on the Function and Application of Thymosin β4 | — |
| Frontiers in Endocrinology |
| June 13, 2026 | Source | New source added: A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers | — |
| British Journal of Clinical Pharmacology |
| June 13, 2026 | Source | New source added: Thymosin beta4 accelerates wound healing | — |
| Journal of Investigative Dermatology |
| June 13, 2026 | Source | New source added: Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues | — |
| Trends in Molecular Medicine / Elsevier |
| June 13, 2026 | Source | New source added: Safety Assessment of Palmitoyl Oligopeptides Ingredients as Used in Cosmetics | — |
| Cosmetic Ingredient Review (CIR) |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5: What Can It Do for Your Skin? | — |
| The Dermatology Review |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5 Ingredient Profile | — |
| INCIDecoder |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5: Research in Skin Cell Proliferation and Rejuvenation | — |
| Core Peptides |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5 (Syn-Coll) Peptide and Collagen Production | — |
| Biotech Peptides |
| June 13, 2026 | Source | New source added: Syn-Coll Tripeptide and Skin Cell Architecture | — |
| Biotech Peptides |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5: Collagen Booster Profile | — |
| PeptideJournal.org |
| June 13, 2026 | Source | New source added: The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action | — |
| Journal of Biological Chemistry |
| June 13, 2026 | Source | New source added: A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER) — NCT03098797 | — |
| ClinicalTrials.gov |
| June 13, 2026 | Source | New source added: Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval | — |
| Drug Discovery and Therapeutics |
| June 13, 2026 | Source | New source added: Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice | — |
| Aging Pathobiology and Therapeutics |
| June 13, 2026 | Source | New source added: SS-31 and NMN: Two paths to improve metabolism and function in aged hearts | — |
| Aging Cell |
| June 13, 2026 | Source | New source added: Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide | — |
| Circulation: Heart Failure |
| June 13, 2026 | Source | New source added: FORZINITY (elamipretide hydrochloride) Prescribing Information | — |
| U.S. National Library of Medicine / Stealth BioTherapeutics |
| June 13, 2026 | Source | New source added: Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Functional effects of splenin32-34 on antibody formation in immunosuppressed mice | — |
| Biomedica Biochimica Acta |
| June 13, 2026 | Source | New source added: Thymopentin and splenopentin as immunomodulators. Current status | — |
| Immunologic Research |
| June 13, 2026 | Source | New source added: Splenopentin (DAc-SP5)--influence on engraftment and graft-vs-host reaction after non-H-2 bone marrow transplantation in mice | — |
| Experimental and Clinical Endocrinology |
| June 13, 2026 | Source | New source added: Diacetyl-splenopentin (BCH 069) did not affect the concentrations of various hormones in men | — |
| Experimental and Clinical Endocrinology |
| June 13, 2026 | Source | New source added: Clinical, biochemical and immunological effectiveness of diacetyl-splenopentin (BCH 069) in hay fever | — |
| Allergologia et Immunopathologia |
| June 13, 2026 | Source | New source added: The effect of splenopentin (DA SP-5) on in vitro myelopoiesis and on AZT-induced bone marrow toxicity | — |
| International Journal of Immunopharmacology |
| June 13, 2026 | Source | New source added: Splenopentin (DAc-SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in mice | — |
| International Journal of Immunopharmacology |
| June 13, 2026 | Source | New source added: Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen | — |
| Proceedings of the National Academy of Sciences USA |
| June 13, 2026 | Source | New source added: Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry | — |
| Journal of Analytical Science and Technology |
| June 13, 2026 | Source | New source added: A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells | — |
| Journal of Biological Chemistry |
| June 13, 2026 | Source | New source added: The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study | — |
| American Journal of Clinical Dermatology |
| June 13, 2026 | Source | New source added: An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skin | — |
| Journal of Drugs in Dermatology |
| June 13, 2026 | Source | New source added: Peptide-pro complex serum: Investigating effects on aged skin | — |
| June 13, 2026 | Source | New source added: Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review | — |
| MDPI |
| June 13, 2026 | Source | New source added: Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy | — |
| Frontiers in Chemistry |
| June 13, 2026 | Source | New source added: Sermorelin - Wikipedia | — |
| Wikipedia |
| June 13, 2026 | Source | New source added: What Should Athletes Know About Sermorelin? | — |
| United States Anti-Doping Agency (USADA) |
| June 13, 2026 | Source | New source added: Sermorelin Acetate: Prescribing Information | — |
| RxList / WebMD |
| June 13, 2026 | Source | New source added: Growth Hormone and Aging - Endotext | — |
| NCBI Bookshelf (Endotext / MDText.com) |
| June 13, 2026 | Source | New source added: Treating age-related changes in somatotrophic hormones, sleep, and cognition | — |
| Dialogues in Clinical Neuroscience |
| June 13, 2026 | Source | New source added: Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males | — |
| Translational Andrology and Urology |
| June 13, 2026 | Source | New source added: Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]Growth Hormone-Releasing Hormone-(1-29)-NH2 in Age-Advanced Men and Women | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 13, 2026 | Source | New source added: Zadaxin (Thymalfasin): Side Effects, Uses, Dosage, Interactions, Warnings | — |
| June 13, 2026 | Source | New source added: Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells | — |
| June 13, 2026 | Source | New source added: Immune Modulation with Thymosin Alpha 1 Treatment | — |
| June 13, 2026 | Source | New source added: Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of 27 randomized controlled trials | — |
| PubMed / NCBI |
| June 13, 2026 | Source | New source added: Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study | — |
| June 13, 2026 | Source | New source added: Thymosin-alpha1 for Sepsis Management: A Systematic Review and Meta-Analysis of 1972 Patients | — |
| June 13, 2026 | Source | New source added: Thymosin alpha 1: A comprehensive review of the literature | — |
| Vitamins and Hormones, Academic Press |
| June 13, 2026 | Source | New source added: THYMALIN (Thymus Extract) product page — RuPharma | — |
| June 13, 2026 | Source | New source added: Natural and synthetic thymic peptides as therapeutics for immune dysfunction | — |
| International Journal of Immunopharmacology |
| June 13, 2026 | Source | New source added: Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials | — |
| Advances in Gerontology (Springer Nature) |
| June 13, 2026 | Source | New source added: Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients | — |
| Advances in Gerontology (Springer Nature) |
| June 13, 2026 | Source | New source added: The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19 | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19 | — |
| Stem Cell Reviews and Reports |
| June 13, 2026 | Source | New source added: Peptides of pineal gland and thymus prolong human life | — |
| Neuro Endocrinology Letters |
| June 13, 2026 | Source | New source added: FORTEO (teriparatide) Prescribing Information — DailyMed | — |
| U.S. National Library of Medicine / FDA |
| June 13, 2026 | Source | New source added: Teriparatide - StatPearls | — |
| NCBI Bookshelf / StatPearls |
| June 13, 2026 | Source | New source added: The why and how of sequential and combination therapy in osteoporosis: a review of the current evidence | — |
| June 13, 2026 | Source | New source added: Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review | — |
| June 13, 2026 | Source | New source added: Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates | — |
| June 13, 2026 | Source | New source added: Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis | — |
| New England Journal of Medicine |
| June 13, 2026 | Source | New source added: Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial | — |
| The Lancet |
| June 13, 2026 | Source | New source added: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (Fracture Prevention Trial) | — |
| New England Journal of Medicine |
| June 13, 2026 | Source | New source added: Thymosin beta-4 — Wikipedia | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: TB-500 — Wikipedia | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis | — |
| Kidney International |
| June 13, 2026 | Source | New source added: A Dose Response Study of Thymosin β4 for the Treatment of Acute Stroke | — |
| Journal of Neurological Sciences |
| June 13, 2026 | Source | New source added: RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model | — |
| Scientific Reports |
| June 13, 2026 | Source | New source added: Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | — |
| Oncotarget |
| June 13, 2026 | Source | New source added: A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction (NCT01311518) | — |
| ClinicalTrials.gov |
| June 13, 2026 | Source | New source added: Progress on the Function and Application of Thymosin β4 | — |
| Frontiers in Endocrinology |
| June 13, 2026 | Source | New source added: Thymosin β4 Promotes Dermal Healing | — |
| Vitamins and Hormones |
| June 13, 2026 | Source | New source added: Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing | — |
| Annals of the New York Academy of Sciences |
| June 13, 2026 | Source | New source added: 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications | — |
| Expert Opinion on Biological Therapy |
| June 13, 2026 | Source | New source added: Biological activities of thymosin beta4 defined by active sites in short peptide sequences | — |
| FASEB Journal |
| June 13, 2026 | Source | New source added: The actin binding site on thymosin beta4 promotes angiogenesis | — |
| FASEB Journal |
| June 13, 2026 | Source | New source added: YK-11 — Wikipedia | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: Detection of selective androgen receptor modulator YK-11 in a doping control sample (Sobolevsky et al., 2024) | — |
| Drug Testing and Analysis |
| June 13, 2026 | Source | New source added: Studies on the in vivo metabolism of the SARM YK11: identification and characterization of metabolites potentially useful for doping controls (Piper et al., 2018) | — |
| Drug Testing and Analysis |
| June 13, 2026 | Source | New source added: YK11 promotes osteogenic differentiation of BMSCs and repair of bone defects (Wang et al., 2025) | — |
| Journal of Molecular Endocrinology |
| June 13, 2026 | Source | New source added: Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis (Lee et al., 2021) | — |
| Biochemical and Biophysical Research Communications |
| June 13, 2026 | Source | New source added: Selective androgen receptor modulator YK11 regulates myogenic differentiation of C2C12 myoblasts by follistatin expression (Kanno et al., 2013) | — |
| Biological and Pharmaceutical Bulletin |
| June 13, 2026 | Source | New source added: YK11 is a partial agonist of the androgen receptor (Kanno et al., 2011) | — |
| Biological and Pharmaceutical Bulletin |
| June 13, 2026 | Source | New source added: NCT06917404 – A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium in Knee Osteoarthritis Pain | — |
| June 13, 2026 | Source | New source added: Pentosan Polysulfate: Mechanism, Adverse Effects, Contraindications, and Dosage | — |
| June 13, 2026 | Source | New source added: Pentosan Polysulfate Maculopathy - StatPearls | — |
| NCBI Bookshelf / StatPearls |
| June 13, 2026 | Source | New source added: Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues | — |
| June 13, 2026 | Source | New source added: Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial | — |
| June 13, 2026 | Source | New source added: The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study | — |
| June 13, 2026 | Source | New source added: Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double-blind, placebo-controlled, randomized study | — |
| June 13, 2026 | Source | New source added: Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials | — |
| Current Medical Research and Opinion |
| June 13, 2026 | Source | New source added: Pegzilarginase — Wikipedia | — |
| June 13, 2026 | Source | New source added: Pegzilarginase for Arginase-1 deficiency — NIHR Evidence Scan | — |
| National Institute for Health Research (NIHR) |
| June 13, 2026 | Source | New source added: FDA Grants Accelerated Approval to Pegzilarginase for Arginase 1 Deficiency | — |
| Pharmacy Times |
| June 13, 2026 | Source | New source added: Arginase 1 deficiency: a treatable form of spastic paraplegia | — |
| June 13, 2026 | Source | New source added: U.S. FDA has granted accelerated approval of Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with Arginase 1 Deficiency (ARG1-D) | — |
| Immedica Pharma via PR Newswire |
| June 13, 2026 | Source | New source added: LOARGYS (pegzilarginase-nbln) injection — DailyMed Prescribing Label | — |
| June 13, 2026 | Source | New source added: Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial | — |
| eClinicalMedicine (The Lancet) |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation | — |
| Biomedicines (MDPI) |
| June 13, 2026 | Source | New source added: Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants: A Double-Blind Randomised Controlled Study | — |
| Nutrients (MDPI) |
| June 13, 2026 | Source | New source added: Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential | — |
| Food Science and Nutrition |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide: A Natural Compound for Health Management | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism | — |
| Mediators of Inflammation |
| June 13, 2026 | Source | New source added: Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial | — |
| Pain |
| June 13, 2026 | Source | New source added: A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain | — |
| Pain and Therapy |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials | — |
| Nutrients (MDPI) |
| June 13, 2026 | Source | New source added: Syn-Coll (Palmitoyl Tripeptide-5) — Active Ingredient Safety Data | — |
| Roots by Benda |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5 (Explained + Products) | — |
| INCIDecoder |
| June 13, 2026 | Source | New source added: Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics | — |
| Cosmetic Ingredient Review (CIR) |
| June 13, 2026 | Source | New source added: Function of Palmitoyl Tripeptide-5 | — |
| Creative Peptides |
| June 13, 2026 | Source | New source added: Activation of latent transforming growth factor-beta by thrombospondin-1: mechanisms and physiology | — |
| Core Peptides (cites Murphy-Ullrich & Poczatek 2000, DOI 10.1016/s1359-6101(99)00029-5) |
| June 13, 2026 | Source | New source added: Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles | — |
| Journal of Clinical and Aesthetic Dermatology |
| June 13, 2026 | Source | New source added: Role of topical peptides in preventing or treating aged skin | — |
| International Journal of Cosmetic Science |
| June 13, 2026 | Source | New source added: Palmitoyl tripeptide-5 — Compound Summary (CID 11950477) | — |
| National Center for Biotechnology Information (NCBI) |
| June 13, 2026 | Source | New source added: Peptide 021 - Wikipedia | — |
| June 13, 2026 | Source | New source added: Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease | — |
| Magnetic Resonance Imaging / Elsevier |
| June 13, 2026 | Source | New source added: Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder | — |
| Journal of Neurodevelopmental Disorders |
| June 13, 2026 | Source | New source added: Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome | — |
| Scientific Reports / Nature Publishing Group |
| June 13, 2026 | Source | New source added: Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound | — |
| Alzheimer's Research & Therapy / BioMed Central |
| June 13, 2026 | Source | New source added: Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease | — |
| Molecular Neurodegeneration / BioMed Central |
| June 13, 2026 | Source | New source added: Beneficial Effect of a CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and Spatial Memory in Mice | — |
| Journal of Alzheimer's Disease / IOS Press |
| June 13, 2026 | Source | New source added: Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice | — |
| FEBS Letters / Wiley |
| June 13, 2026 | Source | New source added: Semax - Wikipedia | — |
| June 13, 2026 | Source | New source added: [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency] | — |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: [Effectiveness of semax in acute period of hemispheric ischemic stroke] | — |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress | — |
| European Journal of Pharmacology |
| June 13, 2026 | Source | New source added: The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease | — |
| Acta Naturae |
| June 13, 2026 | Source | New source added: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats | — |
| Genes (MDPI) |
| June 13, 2026 | Source | New source added: Semax, An ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents | — |
| Neurochemical Research |
| June 13, 2026 | Source | New source added: Semax — Cognitive Vitality For Researchers | — |
| Alzheimer's Drug Discovery Foundation |
| June 13, 2026 | Source | New source added: Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: The efficacy of semax in the treatment of patients at different stages of ischemic stroke | — |
| June 13, 2026 | Source | New source added: Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia | — |
| Cellular and Molecular Neurobiology |
| June 13, 2026 | Source | New source added: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents | — |
| Neurochemical Research |
| June 13, 2026 | Source | New source added: Effects of Semax on the Default Mode Network of the Brain | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus | — |
| Brain Research |
| June 13, 2026 | Source | New source added: N-Acetyl Selank Amidate: Reviews, Clinical Studies, and Safety | — |
| Peptides.org |
| June 13, 2026 | Source | New source added: Selank — Wikipedia | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: Immunomodulatory effects of selank in patients with anxiety-asthenic disorders | — |
| Zh Nevrol Psikhiatr Im S S Korsakova |
| June 13, 2026 | Source | New source added: The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats | — |
| Behavioural Neurology |
| June 13, 2026 | Source | New source added: Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity | — |
| June 13, 2026 | Source | New source added: GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells | — |
| June 13, 2026 | Source | New source added: Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment in Rodents | — |
| June 13, 2026 | Source | New source added: Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission | — |
| June 13, 2026 | Source | New source added: [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders] | — |
| Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity | — |
| June 13, 2026 | Source | New source added: Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats | — |
| Behavioural Neurology (Wiley) |
| June 13, 2026 | Source | New source added: [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] | — |
| Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: The protective role of ginsenoside Rg3 in heart diseases and mental disorders | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: Acute and repeated dose 26-week oral toxicity study of 20(S)-ginsenoside Rg3 in Kunming mice and Sprague-Dawley rats | — |
| June 13, 2026 | Source | New source added: Ginsenoside Rg3 Prevents Cognitive Impairment by Improving Mitochondrial Dysfunction in the Rat Model of Alzheimer's Disease | — |
| Journal of Agricultural and Food Chemistry |
| June 13, 2026 | Source | New source added: Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical study | — |
| Oncotarget |
| June 13, 2026 | Source | New source added: Rg3-enriched ginseng extract ameliorates scopolamine-induced learning deficits in mice | — |
| BMC Complementary and Alternative Medicine |
| June 13, 2026 | Source | New source added: Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors | — |
| Frontiers in Physiology |
| June 13, 2026 | Source | New source added: Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons | — |
| Biochemical and Biophysical Research Communications |
| June 13, 2026 | Source | New source added: FDA Approves New Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women | — |
| PR Newswire / AMAG Pharmaceuticals |
| June 13, 2026 | Source | New source added: Vyleesi (Bremelanotide Injection) — Official Patient Site | — |
| AMAG Pharmaceuticals |
| June 13, 2026 | Source | New source added: The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results | — |
| Journal of Women's Health |
| June 13, 2026 | Source | New source added: Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder | — |
| PubMed Central |
| June 13, 2026 | Source | New source added: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials | — |
| Obstetrics & Gynecology |
| June 13, 2026 | Source | New source added: FDA Approves New Drug Application for Vyleesi (bremelanotide injection) | — |
| Palatin Technologies |
| June 13, 2026 | Source | New source added: Bremelanotide for Treatment of Female Hypoactive Sexual Desire | — |
| June 13, 2026 | Source | New source added: Bremelanotide - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury | — |
| National Library of Medicine (NIH NCBI Bookshelf) |
| June 13, 2026 | Source | New source added: The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results | — |
| June 13, 2026 | Source | New source added: Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide | — |
| June 13, 2026 | Source | New source added: Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide | — |
| June 13, 2026 | Source | New source added: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials | — |
| Obstetrics & Gynecology |
| June 13, 2026 | Source | New source added: Prostatilen (Prostate Extract - Prostatilenum) 50 mg, 10 suppositories — product listing | — |
| June 13, 2026 | Source | New source added: Our experience in the use of prostatilen in urology | — |
| June 13, 2026 | Source | New source added: The use of prostatilen in treating patients with prostatic adenoma | — |
| June 13, 2026 | Source | New source added: Polypeptide prostatilen in the treatment of patients with complicated prostatitis | — |
| June 13, 2026 | Source | New source added: Effect of prostatilen AC suppositories on course of experimental prostatitis | — |
| June 13, 2026 | Source | New source added: Influence of adding zinc arginyle-glycinate to improve efficacy of bioregulatory peptides of the prostate gland in treatment of patients with impaired sperm parameters | — |
| June 13, 2026 | Source | New source added: Bioregulatory therapy for chronic abacterial prostatitis | — |
| Urology Reports (St. Petersburg), Eco-Vector |
| June 13, 2026 | Source | New source added: Prostatic bioregulatory polypeptide prostatilen: pharmacological properties and 30-year experience of clinical application in urology | — |
| Urology Reports (St. Petersburg), Eco-Vector |
| June 13, 2026 | Source | New source added: Pramlintide - Wikidoc | — |
| June 13, 2026 | Source | New source added: Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes | — |
| JCEM Case Reports / The Endocrine Society |
| June 13, 2026 | Source | New source added: Primer on pramlintide, an amylin analog | — |
| June 13, 2026 | Source | New source added: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients | — |
| Obesity Research |
| June 13, 2026 | Source | New source added: Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets | — |
| June 13, 2026 | Source | New source added: The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis | — |
| Diabetes, Obesity and Metabolism |
| June 13, 2026 | Source | New source added: Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis | — |
| June 13, 2026 | Source | New source added: Pinealon — Wikipedia | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Pinealon protects the rat offspring from prenatal hyperhomocysteinemia | — |
| International Journal of Clinical and Experimental Medicine |
| June 13, 2026 | Source | New source added: Neuroprotective Effects of Tripeptides — Epigenetic Regulators in Mouse Model of Alzheimer's Disease | — |
| MDPI Pharmaceuticals |
| June 13, 2026 | Source | New source added: EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease | — |
| MDPI Molecules |
| June 13, 2026 | Source | New source added: N-Acetyl Semax Amidate: Research Evidence and Safety Profile | — |
| PeptideInsight |
| June 13, 2026 | Source | New source added: Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models | — |
| ACS Chemical Neuroscience |
| June 13, 2026 | Source | New source added: Effects of Semax on the Default Mode Network of the Brain | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia | — |
| Cellular and Molecular Neurobiology |
| June 13, 2026 | Source | New source added: Effects of behaviorally active ACTH(4-10) analogue Semax on rat basal forebrain cholinergic neurons | — |
| Restorative Neurology and Neuroscience |
| June 13, 2026 | Source | New source added: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents | — |
| Neurochemical Research |
| June 13, 2026 | Source | New source added: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus | — |
| Brain Research |
| June 13, 2026 | Source | New source added: Semax - Wikipedia | — |
| Wikimedia Foundation |
| June 12, 2026 | Source | New source added: Metreleptin (Myalept) - Medical Clinical Policy Bulletin | — |
| Aetna |
| June 12, 2026 | Source | New source added: Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies | — |
| Proceedings of the National Academy of Sciences |
| June 12, 2026 | Source | New source added: Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy | — |
| June 12, 2026 | Source | New source added: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency | — |
| Journal of Clinical Investigation |
| June 12, 2026 | Source | New source added: Structural insights into the mechanism of leptin receptor activation | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: New advances in the treatment of generalized lipodystrophy: role of metreleptin | — |
| June 12, 2026 | Source | New source added: Recent advances in understanding leptin signaling and leptin resistance | — |
| American Journal of Physiology |
| June 12, 2026 | Source | New source added: Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms (CedLara) | — |
| ClinicalTrials.gov |
| June 12, 2026 | Source | New source added: Clinical Trial Finds Safe, Effective Treatment for Children with Severe Post-COVID Syndrome | — |
| Mass General Brigham |
| June 12, 2026 | Source | New source added: A systematic review and meta-analysis of randomized controlled trials: Efficacy and safety of larazotide acetate in celiac disease patients undergoing a gluten challenge | — |
| June 12, 2026 | Source | New source added: Larazotide acetate: a pharmacological peptide approach to tight junction regulation | — |
| American Journal of Physiology-Gastrointestinal and Liver Physiology |
| June 12, 2026 | Source | New source added: The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate | — |
| Therapeutic Advances in Gastroenterology |
| June 12, 2026 | Source | New source added: A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge | — |
| June 12, 2026 | Source | New source added: Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study | — |
| Gut |
| June 12, 2026 | Source | New source added: Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial | — |
| Gastroenterology |
| June 12, 2026 | Source | New source added: KPV tripeptide — Wikipedia | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway | — |
| Tissue and Cell (Elsevier) |
| June 12, 2026 | Source | New source added: The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials | — |
| Cells (MDPI) |
| June 12, 2026 | Source | New source added: Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists | — |
| International Journal of Physiology, Pathophysiology and Pharmacology |
| June 12, 2026 | Source | New source added: Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore | — |
| Advances in Experimental Medicine and Biology (Springer) |
| June 12, 2026 | Source | New source added: Antimicrobial effects of alpha-MSH peptides | — |
| Journal of Leukocyte Biology |
| June 12, 2026 | Source | New source added: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation | — |
| Gastroenterology (Elsevier) |
| June 12, 2026 | Source | New source added: Emerging Therapeutic Potential of Kisspeptin and Neurokinin B | — |
| Endocrine Reviews |
| June 12, 2026 | Source | New source added: Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans | — |
| June 12, 2026 | Source | New source added: Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54 | — |
| June 12, 2026 | Source | New source added: Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization | — |
| Journal of Clinical Investigation |
| June 12, 2026 | Source | New source added: The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction | — |
| June 12, 2026 | Source | New source added: IMUNOFAN — Official Manufacturer Information (NPP BIONOX) | — |
| NPP BIONOX, Russia |
| June 12, 2026 | Source | New source added: [The immunocorrective action of the new synthetic hexapeptide imunofan in pharmacologically induced and ecological immunodeficiency] | — |
| Vestnik Rossiiskoi Akademii Meditsinskikh Nauk |
| June 12, 2026 | Source | New source added: P20 - The use of regulatory hexapeptide on frequently ill children | — |
| BMC Infectious Diseases (conference supplement) |
| June 12, 2026 | Source | New source added: Role of immunotherapy in complex treatment of acute optic neuritis associated with herpesvirus infection | — |
| Acta Biomedica Scientifica |
| June 12, 2026 | Source | New source added: [Experimental study of the effectiveness of the use of imunofan in the treatment of viral diseases of the eye] | — |
| June 12, 2026 | Source | New source added: Hydrophilic hexapeptide Imunofan as a hyperactive regulator of transport proteins for multiple drug resistance | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: [A trial of the use of the immunocorrective preparation Imunofan for treating diphtheria] | — |
| Terapevticheskii Arkhiv |
| June 12, 2026 | Source | New source added: Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repair | — |
| MDPI Molecules |
| June 12, 2026 | Source | New source added: Ovagen Peptide: Liver Health, Cellular and Gastrointestinal Bioregulator | — |
| JayCampbell.com |
| June 12, 2026 | Source | New source added: Buy OVAGEN (liver peptides) - product page | — |
| CosmicNootropic |
| June 12, 2026 | Source | New source added: Ovagen - Liver and Gastrointestinal Tract Bioregulator (product information) | — |
| Antiaging Systems |
| June 12, 2026 | Source | New source added: Vladimir Khavinson - Wikipedia | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology | — |
| Advances in Gerontology |
| June 12, 2026 | Source | New source added: Tripeptides slow down aging process in renal cell culture | — |
| Advances in Gerontology |
| June 12, 2026 | Source | New source added: Short Peptides Regulate Gene Expression | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: ATTAIN-Outcomes: Cardiovascular Outcomes Study of Orforglipron (NCT07241390) | — |
| ClinicalTrials.gov / Eli Lilly |
| June 12, 2026 | Source | New source added: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes — PMC | — |
| International Journal of Molecular Sciences / PMC |
| June 12, 2026 | Source | New source added: Orforglipron (LY3502970): Phase 1b Multiple-Ascending-Dose Study in Type 2 Diabetes | — |
| June 12, 2026 | Source | New source added: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes — ACHIEVE-1 Phase 3 | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity in people with type 2 diabetes (ATTAIN-2) — The Lancet | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity Treatment — ATTAIN-1 Phase 3 | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2) | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: FOUNDAYO (orforglipron) tablets — DailyMed FDA Prescribing Information (NDA 220934) | — |
| U.S. National Library of Medicine / FDA |
| June 12, 2026 | Source | New source added: Antidepressant with novel action appears safe and effective in phase 1b clinical trial | — |
| EurekAlert / AAAS |
| June 12, 2026 | Source | New source added: Study of NSI-189 Phosphate for Major Depressive Disorder (NCT02695472) | — |
| June 12, 2026 | Source | New source added: Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder | — |
| June 12, 2026 | Source | New source added: Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189 | — |
| Diabetes (American Diabetes Association) |
| June 12, 2026 | Source | New source added: Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189 | — |
| Neuropharmacology |
| June 12, 2026 | Source | New source added: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients | — |
| Molecular Psychiatry |
| June 12, 2026 | Source | New source added: A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder | — |
| Molecular Psychiatry |
| June 12, 2026 | Source | New source added: FDA declares NMN lawful in dietary supplements | — |
| NutraIngredients |
| June 12, 2026 | Source | New source added: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis | — |
| Journal of Cachexia, Sarcopenia and Muscle |
| June 12, 2026 | Source | New source added: Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials | — |
| Journal of Nutrition and Metabolism |
| June 12, 2026 | Source | New source added: Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule | — |
| Molecules |
| June 12, 2026 | Source | New source added: Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial | — |
| GeroScience |
| June 12, 2026 | Source | New source added: The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: FDA declares NMN lawful in dietary supplements | — |
| NutraIngredients |
| June 12, 2026 | Source | New source added: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis | — |
| Journal of Cachexia, Sarcopenia and Muscle |
| June 12, 2026 | Source | New source added: Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials | — |
| Journal of Nutrition and Metabolism |
| June 12, 2026 | Source | New source added: Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule | — |
| Molecules |
| June 12, 2026 | Source | New source added: Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial | — |
| GeroScience |
| June 12, 2026 | Source | New source added: The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: Navepegritide: Uses, Interactions, Mechanism of Action — DrugBank | — |
| June 12, 2026 | Source | New source added: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older — Ascendis Pharma Press Release | — |
| Ascendis Pharma |
| June 12, 2026 | Source | New source added: New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasia | — |
| Ascendis Pharma / GlobeNewswire |
| June 12, 2026 | Source | New source added: Molecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptide | — |
| June 12, 2026 | Source | New source added: Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics — Pediatric Endocrine Society | — |
| June 12, 2026 | Source | New source added: YUVIWEL (navepegritide) Prescribing Information — DailyMed | — |
| June 12, 2026 | Source | New source added: Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial | — |
| JAMA Pediatrics / PubMed Central |
| June 12, 2026 | Source | New source added: Gonadorelin — Wikipedia | — |
| Wikimedia Foundation |
| June 12, 2026 | Source | New source added: Gonadotropin Releasing Hormone (GnRH) Analogues — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury | — |
| National Institute of Diabetes and Digestive and Kidney Diseases / NCBI Bookshelf |
| June 12, 2026 | Source | New source added: Factrel (Gonadorelin Hydrochloride): Full Prescribing Information — RxList | — |
| RxList / WebMD |
| June 12, 2026 | Source | New source added: Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study | — |
| Translational Andrology and Urology |
| June 12, 2026 | Source | New source added: Spermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysis | — |
| World Journal of Men's Health |
| June 12, 2026 | Source | New source added: Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort | — |
| Journal of Assisted Reproduction and Genetics |
| June 12, 2026 | Source | New source added: Glycine's Role In Sleep Enhancement: Clinical Evidence, Mechanisms, and Therapeutic Applications | — |
| GlobalRPH |
| June 12, 2026 | Source | New source added: Glycine: Health Benefits, Side Effects, Uses, Dose & Precautions | — |
| RxList |
| June 12, 2026 | Source | New source added: Glycine for Sleep | — |
| Sleep Foundation |
| June 12, 2026 | Source | New source added: Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes | — |
| Sleep and Biological Rhythms (Wiley) |
| June 12, 2026 | Source | New source added: Collagen peptide supplementation before bedtime reduces sleep fragmentation and improves cognitive function in physically active males with sleep complaints | — |
| British Journal of Nutrition |
| June 12, 2026 | Source | New source added: The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus | — |
| Neuropsychopharmacology |
| June 12, 2026 | Source | New source added: The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers | — |
| Frontiers in Neurology |
| June 12, 2026 | Source | New source added: Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells | — |
| Drug Design, Development and Therapy |
| June 12, 2026 | Source | New source added: Metabolic Pharmaceuticals AOD9604 Phase 2B Trial Update | — |
| BioSpace |
| June 12, 2026 | Source | New source added: Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa results) | — |
| News-Medical.Net |
| June 12, 2026 | Source | New source added: AOD9604 — Wikipedia | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: HGH Fragment 176-191 — Wikipedia | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans | — |
| Journal of Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice | — |
| Endocrinology (Oxford Academic) |
| June 12, 2026 | Source | New source added: Peptide Sparks Synaptic Plasticity, Improves Memory in Rodents | — |
| Alzforum |
| June 12, 2026 | Source | New source added: The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivo | — |
| June 12, 2026 | Source | New source added: A neural cell adhesion molecule-derived peptide, FGL, attenuates glial cell activation in the aged hippocampus | — |
| June 12, 2026 | Source | New source added: Impact of the Neural Cell Adhesion Molecule-Derived Peptide FGL on Seizure Progression and Cellular Alterations in the Mouse Kindling Model | — |
| June 12, 2026 | Source | New source added: Amyloid-Beta Induced CA1 Pyramidal Cell Loss in Young Adult Rats Is Alleviated by Systemic Treatment with FGL, a Neural Cell Adhesion Molecule-Derived Mimetic Peptide | — |
| June 12, 2026 | Source | New source added: Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteers | — |
| Clinical Pharmacokinetics / Springer |
| June 12, 2026 | Source | New source added: Neuritogenic and Neuroprotective Properties of Peptide Agonists of the Fibroblast Growth Factor Receptor | — |
| June 12, 2026 | Source | New source added: A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo | — |
| June 12, 2026 | Source | New source added: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study | — |
| June 12, 2026 | Source | New source added: Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease | — |
| June 12, 2026 | Source | New source added: Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND | — |
| June 12, 2026 | Source | New source added: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11 | — |
| June 12, 2026 | Source | New source added: Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) | — |
| Diabetes Care / American Diabetes Association |
| June 12, 2026 | Source | New source added: Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program | — |
| June 12, 2026 | Source | New source added: TRULICITY (dulaglutide) Prescribing Information - DailyMed | — |
| U.S. National Library of Medicine / Eli Lilly and Company |
| June 12, 2026 | Source | New source added: N-Acetyl Semax Amidate Dosage Calculator and Chart | — |
| Peptides.org |
| June 12, 2026 | Source | New source added: N-Acetyl Semax Amidate: Reviews, Clinical Trials, and Safety | — |
| Peptides.org |
| June 12, 2026 | Source | New source added: Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10 (NCT05648526) | — |
| ClinicalTrials.gov |
| June 12, 2026 | Source | New source added: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: The efficacy of semax in the treatment of patients at different stages of ischemic stroke | — |
| Zh Nevrol Psikhiatr Im S S Korsakova |
| June 12, 2026 | Source | New source added: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus | — |
| Brain Research |
| June 12, 2026 | Source | New source added: MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner | — |
| Free Radical Biology and Medicine |
| June 12, 2026 | Source | New source added: CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity | — |
| GlobeNewswire / CohBar Inc. |
| June 12, 2026 | Source | New source added: MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases | — |
| Diabetes and Metabolism Journal |
| June 12, 2026 | Source | New source added: MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress | — |
| Cell Metabolism |
| June 12, 2026 | Source | New source added: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance | — |
| Cell Metabolism |
| June 12, 2026 | Source | New source added: Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults | — |
| Journals of Gerontology: Series A |
| June 12, 2026 | Source | New source added: Hepatotoxicity induced by MK-677 | — |
| June 12, 2026 | Source | New source added: Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Effects of oral administration of ibutamoren mesylate on the GH-IGF-I axis in GH-deficient children (Codner et al., 2001) | — |
| Clinical Pharmacology and Therapeutics |
| June 12, 2026 | Source | New source added: Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (Murphy et al., 1998) | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial | — |
| Neurology |
| June 12, 2026 | Source | New source added: Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial (Nass et al., 2008) | — |
| Annals of Internal Medicine |
| June 12, 2026 | Source | New source added: Donepezil and memantine for moderate-to-severe Alzheimer's disease | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: DailyMed - MEMANTINE tablet - Full Prescribing Information | — |
| National Library of Medicine / DailyMed |
| June 12, 2026 | Source | New source added: Memantine in Psychiatry: An Underutilized Therapeutic Breakthrough? | — |
| June 12, 2026 | Source | New source added: Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease | — |
| Neurotoxicity Research / Springer |
| June 12, 2026 | Source | New source added: Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications | — |
| iBrain / Wiley Online Library |
| June 12, 2026 | Source | New source added: Update on the use of memantine in Alzheimer's disease | — |
| Neuropsychiatric Disease and Treatment |
| June 12, 2026 | Source | New source added: Memantine - StatPearls - NCBI Bookshelf | — |
| StatPearls Publishing / NCBI |
| June 12, 2026 | Source | New source added: Safety of higher doses of melatonin in adults: A systematic review and meta-analysis | — |
| Journal of Pineal Research / PMC |
| June 12, 2026 | Source | New source added: A clinical trial with DSIP | — |
| European Neurology |
| June 12, 2026 | Source | New source added: The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep | — |
| Experientia |
| June 12, 2026 | Source | New source added: Delta-sleep-inducing peptide stimulates melatonin, 5-methoxytryptophol and serotonin release from perifused rat pineal glands | — |
| Biological Signals |
| June 12, 2026 | Source | New source added: Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials | — |
| Journal of Sleep Research |
| June 12, 2026 | Source | New source added: Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties | — |
| MDPI / PMC |
| June 12, 2026 | Source | New source added: Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells | — |
| June 12, 2026 | Source | New source added: The emerging role of the mitochondrial-derived peptide humanin in stress resistance | — |
| Journal of Molecular Endocrinology |
| June 12, 2026 | Source | New source added: Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice | — |
| June 12, 2026 | Source | New source added: New Role for the Mitochondrial Peptide Humanin: Protective Agent Against Chemotherapy-Induced Side Effects | — |
| Journal of the National Cancer Institute |
| June 12, 2026 | Source | New source added: Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan | — |
| Aging (Albany NY) |
| June 12, 2026 | Source | New source added: Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans | — |
| Scientific Reports (Nature) |
| June 12, 2026 | Source | New source added: Examorelin — Wikipedia | — |
| June 12, 2026 | Source | New source added: Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity | — |
| Pharmaceuticals (MDPI) |
| June 12, 2026 | Source | New source added: Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats | — |
| June 12, 2026 | Source | New source added: Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction | — |
| June 12, 2026 | Source | New source added: Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery | — |
| European Journal of Pharmacology |
| June 12, 2026 | Source | New source added: Growth Hormone Status during Long-Term Hexarelin Therapy | — |
| Oxford Academic / Endocrine Society |
| June 12, 2026 | Source | New source added: Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study | — |
| Oxford Academic / Endocrine Society |
| June 12, 2026 | Source | New source added: Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man | — |
| Oxford Academic / Endocrine Society |
| June 12, 2026 | Source | New source added: What does Hexapeptide-11 do for skin and hair? — ChemicalBook | — |
| June 12, 2026 | Source | New source added: Hexapeptide-11 ingredient listing — INCIDecoder | — |
| June 12, 2026 | Source | New source added: Peptamide 6 (Hexapeptide-11) — Cosmetic Ingredients Guide | — |
| June 12, 2026 | Source | New source added: Hexapeptide-11 in Skin Care: What It Is and Is It Safe? — Paula's Choice | — |
| June 12, 2026 | Source | New source added: Hexapeptide-11 (CID 24998056) — PubChem Compound | — |
| National Library of Medicine / NIH |
| June 12, 2026 | Source | New source added: Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts (PMC full text) | — |
| Redox Biology (Elsevier) |
| June 12, 2026 | Source | New source added: Modulation of cellular senescence in fibroblasts and dermal papillae cells in vitro | — |
| Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts | — |
| Redox Biology (Elsevier) |
| June 12, 2026 | Source | New source added: Pregnyl (chorionic gonadotropin for injection, USP) Prescribing Information — NDA 017692 | — |
| U.S. Food and Drug Administration |
| June 12, 2026 | Source | New source added: Preserving fertility in the hypogonadal patient: an update | — |
| Asian Journal of Andrology / PMC |
| June 12, 2026 | Source | New source added: The effect of human chorionic gonadotropin (hCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis (DARE review) | — |
| NCBI Bookshelf / Database of Abstracts of Reviews of Effects |
| June 12, 2026 | Source | New source added: The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use | — |
| Cureus |
| June 12, 2026 | Source | New source added: Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins | — |
| Cureus |
| June 12, 2026 | Source | New source added: Testosterone versus hCG in Hypogonadotropic Hypogonadism: Comparing Clinical Effects and Evaluating Current Practice | — |
| Global Pediatric Health |
| June 12, 2026 | Source | New source added: Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro | — |
| Reproductive Biology and Endocrinology / BioMed Central |
| June 12, 2026 | Source | New source added: Imunovir 500mg Tablets — Summary of Product Characteristics (SmPC) | — |
| Electronic Medicines Compendium (UK) |
| June 12, 2026 | Source | New source added: A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients | — |
| Dove Medical Press |
| June 12, 2026 | Source | New source added: Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course | — |
| Viruses (MDPI) |
| June 12, 2026 | Source | New source added: Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study | — |
| International Journal of STD and AIDS |
| June 12, 2026 | Source | New source added: The Efficacy of Inosine Pranobex in Preventing the Acquired Immunodeficiency Syndrome in Patients with Human Immunodeficiency Virus Infection (Scandinavian Isoprinosine Study Group) | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial | — |
| Advanced Therapeutics (Wiley) |
| June 12, 2026 | Source | New source added: Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: Phase 4, randomised, placebo-controlled, double-blind study | — |
| BMC Infectious Diseases |
| June 12, 2026 | Source | New source added: SCENESSE (afamelanotide) Prescribing Information | — |
| U.S. Food and Drug Administration |
| June 12, 2026 | Source | New source added: Melanotan II | — |
| June 12, 2026 | Source | New source added: Melanotan II | — |
| DermNet New Zealand |
| June 12, 2026 | Source | New source added: Eruptive dysplastic nevi following melanotan use | — |
| Actas Dermosifiliograficas |
| June 12, 2026 | Source | New source added: Melanotan-associated melanoma in situ | — |
| Australasian Journal of Dermatology |
| June 12, 2026 | Source | New source added: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II | — |
| International Journal of Impotence Research |
| June 12, 2026 | Source | New source added: Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction | — |
| Urology |
| June 12, 2026 | Source | New source added: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study | — |
| Life Sciences (Elsevier) |
| June 12, 2026 | Source | New source added: Matrixyl 3000 — Official Product Page | — |
| Croda Beauty (Sederma) |
| June 12, 2026 | Source | New source added: Palmitoyl tetrapeptide-7 | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics | — |
| International Journal of Toxicology (Cosmetic Ingredient Review) |
| June 12, 2026 | Source | New source added: Topical Peptide Treatments with Effective Anti-Aging Results | — |
| MDPI Cosmetics |
| June 12, 2026 | Source | New source added: Clinical evidence of the efficacy and safety of a new multi-peptide anti-aging topical eye serum | — |
| Journal of Cosmetic Dermatology |
| June 12, 2026 | Source | New source added: Palmitoyl pentapeptide-4 - Wikipedia | — |
| June 12, 2026 | Source | New source added: Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4, and Pentapeptide-4 as Used in Cosmetics | — |
| Cosmetic Ingredient Review |
| June 12, 2026 | Source | New source added: The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cells | — |
| Journal of Orthopaedic Research |
| June 12, 2026 | Source | New source added: The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity | — |
| Molecules |
| June 12, 2026 | Source | New source added: Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS) | — |
| Biomolecules and Therapeutics |
| June 12, 2026 | Source | New source added: Topically applied KTTKS: a review | — |
| International Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin | — |
| International Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: A pentapeptide from type I procollagen promotes extracellular matrix production | — |
| Journal of Biological Chemistry |
| June 12, 2026 | Source | New source added: LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity | — |
| Pharmacological Reports |
| June 12, 2026 | Source | New source added: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells | — |
| Journal of Experimental Medicine |
| June 12, 2026 | Source | New source added: Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37 | — |
| Journal of Investigative Dermatology |
| June 12, 2026 | Source | New source added: Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial | — |
| Wound Repair and Regeneration / Wiley |
| June 12, 2026 | Source | New source added: Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial | — |
| Wound Repair and Regeneration / Wiley |
| June 12, 2026 | Source | New source added: SCALE Trial Summary - Wiki Journal Club | — |
| June 12, 2026 | Source | New source added: High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination (case series) | — |
| MDPI / Endocrines |
| June 12, 2026 | Source | New source added: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER sub-analysis) | — |
| Journal of the American College of Cardiology |
| June 12, 2026 | Source | New source added: SAXENDA (liraglutide) injection - FDA Prescribing Information | — |
| U.S. Food and Drug Administration / Novo Nordisk |
| June 12, 2026 | Source | New source added: Liraglutide and Renal Outcomes in Type 2 Diabetes (LEADER renal sub-analysis) | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial) | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE trial) | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Liraglutide - StatPearls - NCBI Bookshelf | — |
| NCBI Bookshelf / StatPearls |
| June 12, 2026 | Source | New source added: Oxytocin functions: an overview | — |
| MedCrave Online |
| June 12, 2026 | Source | New source added: Oxytocin: its mechanism of action and receptor signalling in the myometrium | — |
| PubMed / National Library of Medicine |
| June 12, 2026 | Source | New source added: Oxytocin and Women Postpartum Depression: A Systematic Review of Randomized Controlled Trials | — |
| PMC / National Library of Medicine |
| June 12, 2026 | Source | New source added: Oxytocin and postpartum depression: A systematic review | — |
| PubMed / National Library of Medicine |
| June 12, 2026 | Source | New source added: Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial | — |
| PMC / National Library of Medicine |
| June 12, 2026 | Source | New source added: The neurobiological impact of oxytocin in mental health disorders: a comprehensive review | — |
| PMC / National Library of Medicine |
| June 12, 2026 | Source | New source added: Oxytocin - StatPearls | — |
| StatPearls Publishing / NCBI Bookshelf |
| June 12, 2026 | Source | New source added: A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naive Participants With Active Psoriatic Arthritis — ClinicalTrials.gov NCT06878404 | — |
| ClinicalTrials.gov / NIH |
| June 12, 2026 | Source | New source added: Once-daily oral icotrokinra versus placebo and deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2) — ScienceDirect abstract | — |
| The Lancet |
| June 12, 2026 | Source | New source added: ICONIC-LEAD Phase 3: Icotrokinra for Moderate-to-Severe Plaque Psoriasis — Results Through Week 24 (ScienceDirect abstract) | — |
| June 12, 2026 | Source | New source added: FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide — Johnson & Johnson press release | — |
| Johnson & Johnson / PR Newswire |
| June 12, 2026 | Source | New source added: Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis | — |
| PubMed Central / NCBI |
| June 12, 2026 | Source | New source added: Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling | — |
| PubMed Central / NCBI |
| June 12, 2026 | Source | New source added: Label: ICOTYDE (icotrokinra) tablet, film coated — DailyMed, NIH | — |
| U.S. National Library of Medicine / Janssen Biotech Inc. |
| June 12, 2026 | Source | New source added: AOD9604 - Wikipedia | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Detection and in vitro metabolism of AOD9604 | — |
| Drug Testing and Analysis |
| June 12, 2026 | Source | New source added: Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health | — |
| Journal of Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans | — |
| Journal of Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice | — |
| Endocrinology (Oxford Academic) |
| June 12, 2026 | Source | New source added: Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment | — |
| International Journal of Obesity |
| June 12, 2026 | Source | New source added: Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats | — |
| Journal of Molecular Endocrinology |
| June 12, 2026 | Source | New source added: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone | — |
| Hormone Research |
| June 12, 2026 | Source | New source added: Pralmorelin — History and Discovery (Peptide Initiative) | — |
| Peptide Initiative |
| June 12, 2026 | Source | New source added: GHRP-4 — Growth Hormone Releasing Peptide (ProSpec product monograph) | — |
| ProSpec Bio |
| June 12, 2026 | Source | New source added: Growth hormone-releasing peptides: clinical and basic aspects | — |
| June 12, 2026 | Source | New source added: Growth hormone-releasing peptides and their analogs — Camanni F, Ghigo E, Arvat E | — |
| Frontiers in Neuroendocrinology |
| June 12, 2026 | Source | New source added: Growth hormone-releasing peptide (GHRP) — Bowers CY | — |
| Cell Mol Life Sci |
| June 12, 2026 | Source | New source added: The Safety and Efficacy of Growth Hormone Secretagogues | — |
| Sexual Medicine Reviews |
| June 12, 2026 | Source | New source added: Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects | — |
| SAGE Open Medicine |
| June 12, 2026 | Source | New source added: Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions | — |
| PMC / NCBI |
| June 12, 2026 | Source | New source added: Ghrelin accelerates wound healing through GHS-R1a-mediated MAPK-NF-kappaB/GR signaling pathways in combined radiation and burn injury in rats | — |
| Scientific Reports |
| June 12, 2026 | Source | New source added: The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers | — |
| Journal of Cachexia, Sarcopenia and Muscle |
| June 12, 2026 | Source | New source added: ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia | — |
| Annals of Oncology |
| June 12, 2026 | Source | New source added: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials | — |
| Lancet Oncology |
| June 12, 2026 | Source | New source added: Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial | — |
| Annals of Internal Medicine |
| June 12, 2026 | Source | New source added: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Ipamorelin, the first selective growth hormone secretagogue | — |
| European Journal of Endocrinology |
| June 12, 2026 | Source | New source added: The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial (EurekAlert press release, McGill University / Wayne Carey MD) | — |
| June 12, 2026 | Source | New source added: Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review | — |
| Medical Sciences |
| June 12, 2026 | Source | New source added: The potential of GHK as an anti-aging peptide | — |
| Aging Pathobiology and Therapeutics |
| June 12, 2026 | Source | New source added: Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway | — |
| Frontiers in Molecular Biosciences |
| June 12, 2026 | Source | New source added: A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK | — |
| Genome Medicine |
| June 12, 2026 | Source | New source added: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration | — |
| BioMed Research International |
| June 12, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Copper peptide GHK-Cu - Wikipedia | — |
| June 12, 2026 | Source | New source added: Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review | — |
| International Journal of Medical Sciences (Ivyspring) |
| June 12, 2026 | Source | New source added: Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth | — |
| Annals of Dermatology |
| June 12, 2026 | Source | New source added: The potential of GHK as an anti-aging peptide | — |
| Biomolecules |
| June 12, 2026 | Source | New source added: The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health | — |
| Oxidative Medicine and Cellular Longevity |
| June 12, 2026 | Source | New source added: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration | — |
| BioMed Research International |
| June 12, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data | — |
| International Journal of Molecular Sciences (MDPI) |
| June 12, 2026 | Source | New source added: Efficacy of collagen peptide supplementation on bone and muscle health: a meta-analysis | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: Collagen supplementation in skin and orthopedic diseases: A review of the literature | — |
| Heliyon |
| June 12, 2026 | Source | New source added: Evaluation of the Efficacy and Safety of CollaSel PRO Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial | — |
| Journal of Clinical Medicine |
| June 12, 2026 | Source | New source added: Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia | — |
| Journal of Musculoskeletal and Neuronal Interactions |
| June 12, 2026 | Source | New source added: Oral administration of hydrolyzed collagen alleviates pain and enhances functionality in knee osteoarthritis: Results from a randomized, double-blind, placebo-controlled study | — |
| Contemporary Clinical Trials Communications |
| June 12, 2026 | Source | New source added: The Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Review | — |
| Orthopedic Reviews |
| June 12, 2026 | Source | New source added: Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials | — |
| Journal of Orthopaedic Surgery and Research |
| June 12, 2026 | Source | New source added: Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women — A Randomized Controlled Study | — |
| Nutrients |
| June 12, 2026 | Source | New source added: Cerebrolysin: Cognitive Vitality Rating | — |
| Alzheimer's Drug Discovery Foundation |
| June 12, 2026 | Source | New source added: Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin | — |
| European Journal of Neurology |
| June 12, 2026 | Source | New source added: Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent | — |
| Journal of Neural Transmission |
| June 12, 2026 | Source | New source added: Combined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysis | — |
| Frontiers in Neurology |
| June 12, 2026 | Source | New source added: Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis | — |
| Brain Sciences, MDPI |
| June 12, 2026 | Source | New source added: Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials | — |
| Dementia and Geriatric Cognitive Disorders, Karger |
| June 12, 2026 | Source | New source added: Cerebrolysin for acute ischaemic stroke (Cochrane Review, 7th edition) | — |
| Cochrane |
| June 12, 2026 | Source | New source added: Calcitonin Salmon Injection — Full Prescribing Information (DailyMed) | — |
| U.S. National Library of Medicine / FDA |
| June 12, 2026 | Source | New source added: Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures | — |
| Orthopedic Reviews |
| June 12, 2026 | Source | New source added: The safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly: a pharmacovigilance and RCT meta-analysis | — |
| Frontiers in Pharmacology |
| June 12, 2026 | Source | New source added: Efficacy of calcitonin for treating acute pain associated with osteoporotic vertebral compression fracture: an updated systematic review | — |
| Canadian Journal of Emergency Medicine |
| June 12, 2026 | Source | New source added: Calcitonin — StatPearls | — |
| StatPearls / NCBI Bookshelf (NIH) |
| June 12, 2026 | Source | New source added: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study (PROOF) | — |
| American Journal of Medicine |
| June 12, 2026 | Source | New source added: Cagrilintide-semaglutide as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3) | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management (phase 1b trial) | — |
| The Lancet |
| June 12, 2026 | Source | New source added: The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies | — |
| The Innovation Medicine |
| June 12, 2026 | Source | New source added: REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placebo | — |
| American College of Cardiology |
| June 12, 2026 | Source | New source added: Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management | — |
| Novo Nordisk / PR Newswire |
| June 12, 2026 | Source | New source added: Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes (phase 2 trial) | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: NeuroFGL: Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders (EU CORDIS FP7 project 278006) | — |
| June 12, 2026 | Source | New source added: The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent manner | — |
| June 12, 2026 | Source | New source added: Impact of the Neural Cell Adhesion Molecule-Derived Peptide FGL on Seizure Progression and Cellular Alterations in the Mouse Kindling Model (PMC) | — |
| June 12, 2026 | Source | New source added: The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo | — |
| June 12, 2026 | Source | New source added: A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35 | — |
| June 12, 2026 | Source | New source added: Peptide Sparks Synaptic Plasticity, Improves Memory in Rodents (ALZFORUM, covering Esteban et al. PLoS Biology 2012) | — |
| June 12, 2026 | Source | New source added: Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteers (Clinical Pharmacokinetics, 2007) | — |
| Clinical Pharmacokinetics / Springer |
| June 12, 2026 | Source | New source added: A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo | — |
| June 12, 2026 | Source | New source added: Epitalon: Evidence, telomere protection, aging, and longevity review | — |
| June 12, 2026 | Source | New source added: Peptide Epitalon activates chromatin at the old age | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Structural basis for the inhibition of activin signalling by follistatin | — |
| The EMBO Journal |
| June 12, 2026 | Source | New source added: A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy | — |
| Molecular Therapy |
| June 12, 2026 | Source | New source added: Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Epitalon: What can this peptide do for telomere protection, aging, and longevity, and where is the evidence? | — |
| Healthspan |
| June 12, 2026 | Source | New source added: Epitalon influences pineal secretion in stress-exposed rats in the daytime | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity | — |
| Biogerontology (Springer) |
| June 12, 2026 | Source | New source added: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people | — |
| Advances in Gerontology |
| June 12, 2026 | Source | New source added: Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties | — |
| International Journal of Molecular Sciences (MDPI) |
| June 12, 2026 | Source | New source added: Epitalon — Wikipedia | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity | — |
| Biogerontology (Springer Nature) |
| June 12, 2026 | Source | New source added: Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa | — |
| Neuroendocrinology Letters |
| June 12, 2026 | Source | New source added: Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties | — |
| International Journal of Molecular Sciences (MDPI) |
| June 12, 2026 | Source | New source added: Mechanism of delta-sleep inducing peptide geroprotective activity | — |
| June 12, 2026 | Source | New source added: Synthetic delta-sleep-inducing peptide improves sleep in insomniacs | — |
| Lancet |
| June 12, 2026 | Source | New source added: Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain | — |
| June 12, 2026 | Source | New source added: Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors | — |
| Neuropsychobiology |
| June 12, 2026 | Source | New source added: Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP) | — |
| European Neurology |
| June 12, 2026 | Source | New source added: Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study | — |
| European Neurology |
| June 12, 2026 | Source | New source added: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study | — |
| June 12, 2026 | Source | New source added: Delta sleep-inducing peptide (DSIP): a still unresolved riddle | — |
| Journal of Neurochemistry |
| June 12, 2026 | Source | New source added: Dihexa: Research Evidence and Safety Profile | — |
| June 12, 2026 | Source | New source added: Fosgonimeton — Alzforum Therapeutics Database | — |
| June 12, 2026 | Source | New source added: Four papers by Athira CEO earn expressions of concern | — |
| June 12, 2026 | Source | New source added: AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway | — |
| Brain Sciences |
| June 12, 2026 | Source | New source added: Retraction: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System | — |
| Journal of Pharmacology and Experimental Therapeutics |
| June 12, 2026 | Source | New source added: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System (RETRACTED April 2025) | — |
| Journal of Pharmacology and Experimental Therapeutics |
| June 12, 2026 | Source | New source added: Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents (Notice of Concern, 2021) | — |
| Journal of Pharmacology and Experimental Therapeutics |
| June 12, 2026 | Source | New source added: INTRAROSA (prasterone) Prescribing Information | — |
| Endoceutics Inc. |
| June 12, 2026 | Source | New source added: Should Dehydroepiandrosterone Be Administered to Women? | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing IVF: a randomized controlled trial | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: The effect of dehydroepiandrosterone (DHEA) supplementation on estradiol levels in women: A dose-response and meta-analysis of randomized clinical trials | — |
| PubMed |
| June 12, 2026 | Source | New source added: Effects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life: The DHEA and Well-Ness (DAWN) Trial | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: The Sex Hormone Precursors Dehydroepiandrosterone (DHEA) and Its Sulfate Ester Form (DHEAS): Molecular Mechanisms and Actions on Human Body | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay | — |
| Biomedicines (MDPI) |
| June 12, 2026 | Source | New source added: An open clinical trial of cortexin in treatment of brain ischemia | — |
| June 12, 2026 | Source | New source added: The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis | — |
| ScienceDirect / PMC |
| June 12, 2026 | Source | New source added: Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children | — |
| MedCrave Journal of Neurology and Stroke |
| June 12, 2026 | Source | New source added: Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke | — |
| June 12, 2026 | Source | New source added: Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study) | — |
| June 12, 2026 | Source | New source added: Molecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexin | — |
| Neuroscience and Behavioral Physiology (Springer) |
| June 12, 2026 | Source | New source added: Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Cortagen — Wikipedia | — |
| June 12, 2026 | Source | New source added: Epigenetic Regulation of Aged Heterochromatin by Peptide Bioregulator Cortagen | — |
| International Journal of Peptide Research and Therapeutics |
| June 12, 2026 | Source | New source added: Neuroprotective Effects of Peptides during Ischemic Preconditioning (Zarubina and Shabanov 2016) | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Modulatory Effects of Cortexin and Cortagen on Locomotor Activity and Anxiety-Related Behavior in Mice (Adriani et al.) | — |
| The Open Neuropsychopharmacology Journal |
| June 12, 2026 | Source | New source added: Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia | — |
| Eksperimental'naia i Klinicheskaia Farmakologiia |
| June 12, 2026 | Source | New source added: Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray | — |
| Neuroendocrinology Letters |
| June 12, 2026 | Source | New source added: Tissue-specific effects of peptides (Khavinson VK; organotypic culture with Cortagen, Epithalon, Livagen, Vilon) | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Effect of tetrapeptide cortagen on regeneration of sciatic nerve | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586) | — |
| ClinicalTrials.gov / NLM |
| June 12, 2026 | Source | New source added: Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial | — |
| EurekAlert / AAAS |
| June 12, 2026 | Source | New source added: GHK-Cu: Beyond Cosmetic Hype — Clinical Uses, Stability and Compounding Tips | — |
| Fagron Academy |
| June 12, 2026 | Source | New source added: Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin | — |
| Archives of Facial Plastic Surgery |
| June 12, 2026 | Source | New source added: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration | — |
| BioMed Research International |
| June 12, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Bulevirtide – Wikipedia | — |
| June 12, 2026 | Source | New source added: Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (MYR301) – NCT03852719 | — |
| June 12, 2026 | Source | New source added: FDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus | — |
| Gilead Sciences |
| June 12, 2026 | Source | New source added: Comparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysis | — |
| June 12, 2026 | Source | New source added: Treating hepatitis D with bulevirtide – Real-world experience from 114 patients | — |
| June 12, 2026 | Source | New source added: Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48 | — |
| June 12, 2026 | Source | New source added: Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update | — |
| June 12, 2026 | Source | New source added: Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: BPC-157: The peptide with big claims and scant evidence | — |
| STAT News |
| June 12, 2026 | Source | New source added: Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Potent induction of trained immunity by Saccharomyces cerevisiae beta-glucans | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: Effects of a β-Glucan-Rich Blend of Medicinal Mushrooms and Botanicals on Innate Immune Cell Activation and Function Are Enhanced by a Very Low Dose of Bovine Colostrum Peptides | — |
| Nutrients (MDPI) |
| June 12, 2026 | Source | New source added: Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures | — |
| BMC Cancer |
| June 12, 2026 | Source | New source added: Effect and Tolerability of ABB C1 Beta-Glucan/Selenium/Zinc with Influenza or COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study | — |
| Nutrients (MDPI) |
| June 12, 2026 | Source | New source added: The Effects of Orally Administered Beta-Glucan on Innate Immune Responses in Humans, a Randomized Open-Label Intervention Pilot-Study | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application | — |
| Journal of Fungi (MDPI) |
| June 12, 2026 | Source | New source added: Beta-Glucan Recognition by the Innate Immune System (PMC6618291) | — |
| Nature Reviews Immunology |
| June 12, 2026 | Source | New source added: Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials | — |
| Molecules (MDPI) |
| June 12, 2026 | Source | New source added: The Peptide Argireline: The Importance of Local Application on the Skin, in the Light of Current Knowledge | — |
| Letters in Drug Design and Discovery |
| June 12, 2026 | Source | New source added: Safety Assessment of Acetyl Hexapeptide-8 and Acetyl Hexapeptide-8 Amide as Used in Cosmetics | — |
| Cosmetic Ingredient Review |
| June 12, 2026 | Source | New source added: Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification | — |
| Scientific Reports |
| June 12, 2026 | Source | New source added: Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysis | — |
| GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW |
| June 12, 2026 | Source | New source added: Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy | — |
| European Journal of Neurology |
| June 12, 2026 | Source | New source added: The anti-wrinkle efficacy of Argireline | — |
| Journal of Cosmetic and Laser Therapy |
| June 12, 2026 | Source | New source added: The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects: A Randomized, Placebo-Controlled Study | — |
| American Journal of Clinical Dermatology |
| June 12, 2026 | Source | New source added: A synthetic hexapeptide (Argireline) with antiwrinkle activity | — |
| International Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis (NCT02039687) | — |
| ClinicalTrials.gov |
| June 12, 2026 | Source | New source added: Araim Pharmaceuticals Receives Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis | — |
| PR Newswire |
| June 12, 2026 | Source | New source added: Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain | — |
| Investigative Ophthalmology and Visual Science |
| June 12, 2026 | Source | New source added: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes | — |
| June 12, 2026 | Source | New source added: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response | — |
| Molecular Pain |
| June 12, 2026 | Source | New source added: ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density | — |
| Molecular Medicine |
| June 12, 2026 | Source | New source added: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study | — |
| Molecular Medicine |
| June 12, 2026 | Source | New source added: Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy (PMC3136748 — cites AOD9604 trial data) | — |
| Clinical Pharmacology and Therapeutics / PMC |
| June 12, 2026 | Source | New source added: Obesity Pharmacotherapy: Current Perspectives and Future Directions (PMC3584306 — includes AOD9604 Phase IIb failure summary) | — |
| Current Hypertension Reports / PMC |
| June 12, 2026 | Source | New source added: Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa 12-week trial report) | — |
| News-Medical.net |
| June 12, 2026 | Source | New source added: Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model | — |
| Annals of Clinical and Laboratory Science |
| June 12, 2026 | Source | New source added: Detection and in vitro metabolism of AOD9604 | — |
| Drug Testing and Analysis |
| June 12, 2026 | Source | New source added: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone | — |
| Hormone Research |
| June 12, 2026 | Source | New source added: Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice | — |
| Endocrinology (Oxford Academic) |
| June 12, 2026 | Source | New source added: Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment | — |
| International Journal of Obesity and Related Metabolic Disorders |
| June 12, 2026 | Source | New source added: The role of AMPK in macrophage metabolism, function and polarisation | — |
| Journal of Translational Medicine |
| June 12, 2026 | Source | New source added: AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections | — |
| Scientific Reports |
| June 12, 2026 | Source | New source added: AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review | — |
| Cells (MDPI) |
| June 12, 2026 | Source | New source added: AMPK-dependent and independent effects of AICAR and compound C on T-cell responses | — |
| Oncotarget |
| June 12, 2026 | Source | New source added: AMPK integrates metabolite and kinase-based immunometabolic control in macrophages | — |
| Molecular Metabolism |
| June 12, 2026 | Source | New source added: AMP-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype | — |
| Journal of Immunology |
| June 12, 2026 | Source | New source added: AMPK-derived peptides reduce blood glucose levels but lead to fat retention in the liver of obese mice | — |
| Journal of Endocrinology |
| June 12, 2026 | Source | New source added: Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin) in Ischemic Stroke | — |
| MDPI / International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Actovegin in the management of patients after ischemic stroke: A systematic review | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO) | — |
| Minerva Medica / International Angiology |
| June 12, 2026 | Source | New source added: ARTEMIDA Trial: A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment | — |
| American Heart Association / Stroke |
| June 12, 2026 | Source | New source added: Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients | — |
| American Diabetes Association / Diabetes Care |
| June 12, 2026 | Source | New source added: ACE-031 0.5 mg/kg q4wk and ACE-031 1.0 mg/kg q2wk in Duchenne Muscular Dystrophy (NCT01099761) | — |
| June 12, 2026 | Source | New source added: UPDATE: ACE-031 Clinical Trials in Duchenne MD | — |
| Muscular Dystrophy Association |
| June 12, 2026 | Source | New source added: Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction | — |
| June 12, 2026 | Source | New source added: Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders? | — |
| June 12, 2026 | Source | New source added: ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial | — |
| Muscle & Nerve |
| June 12, 2026 | Source | New source added: A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers | — |
| Muscle & Nerve |
| June 12, 2026 | Source | New source added: The Why and How of Sequential and Combination Therapy in Osteoporosis: A Review of the Current Evidence | — |
| June 12, 2026 | Source | New source added: TYMLOS (abaloparatide) Injection — Full Prescribing Information, Initial U.S. Approval 2017 | — |
| June 12, 2026 | Source | New source added: Abaloparatide - StatPearls (NCBI Bookshelf) | — |
| StatPearls / NCBI |
| June 12, 2026 | Source | New source added: Effect of Abaloparatide on Vertebral, Nonvertebral, Major Osteoporotic, and Clinical Fractures in a Subset of Postmenopausal Women at Increased Risk of Fracture by FRAX Probability | — |
| June 12, 2026 | Source | New source added: The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial (ATOM) | — |
| Journal of Bone and Mineral Research |
| June 12, 2026 | Source | New source added: Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling | — |
| Endocrinology |
| June 12, 2026 | Source | New source added: ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (ACTIVE) | — |
| JAMA |
| June 12, 2026 | Peptide | Peptide updated: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. |
| June 12, 2026 | Peptide | Peptide updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support |
| June 11, 2026 | Source | New source added: Spotlight on tesamorelin in HIV-associated lipodystrophy | — |
| BioDrugs |
| June 11, 2026 | Source | New source added: Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial | — |
| Lancet HIV |
| June 11, 2026 | Source | New source added: Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors | — |
| June 11, 2026 | Source | New source added: Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial | — |
| June 11, 2026 | Source | New source added: Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial | — |
| June 11, 2026 | Source | New source added: Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf | — |
| CADTH |
| June 11, 2026 | Source | New source added: Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy | — |
| June 11, 2026 | Source | New source added: Label: EGRIFTA SV - tesamorelin kit - DailyMed | — |
| U.S. National Library of Medicine / FDA |
| June 11, 2026 | Source | New source added: Ipamorelin - Wikipedia | — |
| June 11, 2026 | Source | New source added: Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074) | — |
| June 11, 2026 | Source | New source added: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats | — |
| Journal of Endocrinology |
| June 11, 2026 | Source | New source added: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats | — |
| Growth Hormone and IGF Research |
| June 11, 2026 | Source | New source added: Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients | — |
| International Journal of Colorectal Disease |
| June 11, 2026 | Source | New source added: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers | — |
| Pharmaceutical Research |
| June 11, 2026 | Source | New source added: Ipamorelin, the first selective growth hormone secretagogue | — |
| European Journal of Endocrinology |
| June 11, 2026 | Source | New source added: Pharmacy Compounding Advisory Committee (PCAC) Meeting — Federal Register Notice, Bulk Drug Substances Including CJC-1295 | — |
| U.S. Food and Drug Administration / Federal Register |
| June 11, 2026 | Source | New source added: CJC-1295 Use in Sports and Military Rules Explained | — |
| Banned Substances Control Group (BSCG) |
| June 11, 2026 | Source | New source added: Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295 — Oxford Academic abstract | — |
| Oxford University Press / JCEM |
| June 11, 2026 | Source | New source added: Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295 — Oxford Academic abstract | — |
| Oxford University Press / JCEM |
| June 11, 2026 | Source | New source added: Lipodystrophy study halted after patient death | — |
| aidsmap |
| June 11, 2026 | Source | New source added: CJC-1295 — Wikipedia | — |
| Wikimedia Foundation |
| June 11, 2026 | Source | New source added: Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog | — |
| Journal of Clinical Endocrinology & Metabolism |
| June 11, 2026 | Source | New source added: Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults | — |
| Journal of Clinical Endocrinology & Metabolism |
| June 11, 2026 | Source | New source added: Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective | — |
| Diabetes, Obesity and Metabolism |
| June 11, 2026 | Source | New source added: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) | — |
| New England Journal of Medicine |
| June 11, 2026 | Source | New source added: Once-weekly tirzepatide versus once-daily insulin degludec in patients with type 2 diabetes (SURPASS-3) | — |
| The Lancet |
| June 11, 2026 | Source | New source added: Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials | — |
| International Journal of Clinical Pharmacy |
| June 11, 2026 | Source | New source added: Tirzepatide - StatPearls | — |
| NCBI Bookshelf / StatPearls |
| June 11, 2026 | Source | New source added: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist | — |
| JCI Insight |
| June 11, 2026 | Source | New source added: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) | — |
| New England Journal of Medicine |
| June 11, 2026 | Source | New source added: Semaglutide - StatPearls | — |
| StatPearls Publishing / NCBI Bookshelf |
| June 11, 2026 | Source | New source added: Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity | — |
| Frontiers in Endocrinology |
| June 11, 2026 | Source | New source added: A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus | — |
| International Journal of Molecular Sciences |
| June 11, 2026 | Source | New source added: Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes | — |
| Cardiovascular Diabetology |
| June 11, 2026 | Source | New source added: Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials | — |
| Diabetes, Obesity and Metabolism |
| June 11, 2026 | Source | New source added: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) | — |
| New England Journal of Medicine |
| June 11, 2026 | Source | New source added: WEGOVY (semaglutide) injection prescribing information | — |
| U.S. Food and Drug Administration |
| June 11, 2026 | Source | New source added: OZEMPIC (semaglutide) injection prescribing information | — |
| U.S. Food and Drug Administration |
| June 10, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide | — |
| Int. J. Mol. Sci. (Pickart & Margolina, 2018) |
| June 10, 2026 | Source | New source added: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A — 503A Bulks List (Category 1 & 2) | — |
| U.S. Food and Drug Administration |
| June 10, 2026 | Source | New source added: Thymosin beta-4 activates ILK and promotes cardiac cell migration, survival and cardiac repair | — |
| Nature (Bock-Marquette et al., 2004) |
| June 10, 2026 | Source | New source added: WADA Prohibited List — S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics | — |
| World Anti-Doping Agency |
| June 10, 2026 | Source | New source added: Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review | — |
| Pharmaceuticals (Jozwiak et al., 2025) |
| June 5, 2026 | Research | New research: Retatrutide TRANSCEND-T2D-1 Phase 3: A1C Lowered up to ~2.0% and Weight up to 16.8% at 40 Weeks in Type 2 Diabetes (Eli Lilly, ADA 2026) | Retatrutide |
| Phase 3 TRANSCEND-T2D-1 (manufacturer-reported topline; Eli Lilly press release dated May 28, 2026 ahead of the ADA 86th Scientific Sessions; full results scheduled for presentation at the ADA retatrutide symposium on June 6, 2026): in adults with type 2 diabetes, retatrutide — a |
| June 5, 2026 | Source | New source added: The Latest in GLP-1-Based Therapy to Be Featured at ADA 2026 | — |
| Medscape / American Diabetes Association |
| June 5, 2026 | Research | New research: ADA 2026 Scientific Sessions (June 5-8, New Orleans): First-Time CagriSema REIMAGINE Phase 3 and Oral GLP-1 Readouts Scheduled | CagriSema, Cagrilintide, Semaglutide, Elecoglipron |
| The American Diabetes Association's 86th Scientific Sessions run June 5-8, 2026 in New Orleans, with GLP-1-based therapies featured in seven of eight major clinical-trial result sessions. Phase 3 REIMAGINE 1, 2 and 3 data for CagriSema (cagrilintide + semaglutide, Novo Nordisk) a |
| June 4, 2026 | Research | New research: FDA Confirms 7-Peptide Agenda for July 23–24, 2026 PCAC 503A Bulks-List Review (BPC-157, KPV, TB-500, MOTS-C, DSIP/Emideltide, Semax, Epitalon) | BPC-157, KPV, TB-500, MOTS-C, DSIP (Emideltide), Semax, Epitalon |
| FDA primary source (Pharmacy Compounding Advisory Committee meeting notice; page content current as of 2026-04-15). The PCAC will meet July 23–24, 2026 at FDA White Oak Campus to discuss bulk drug substances nominated for inclusion on the Section 503A Bulks List. The confirmed ag |
| June 4, 2026 | Source | New source added: Merck press release: Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial | — |
| Merck & Co., Inc. (MSD) |
| June 4, 2026 | Research | New research: Enlicitide Decanoate (Oral Macrocyclic Peptide PCSK9 Inhibitor) Reduced LDL-C 55.8% in Phase 3 CORALreef Lipids (Merck, AHA 2025) | Enlicitide decanoate (MK-0616) |
| Investigational once-daily ORAL macrocyclic peptide PCSK9 inhibitor (Merck/MSD; MK-0616). Late-breaking Phase 3 CORALreef Lipids results presented at AHA Scientific Sessions 2025 (announced 8 Nov 2025): in adults with or at risk for atherosclerotic cardiovascular disease on backg |
| June 3, 2026 | Source | New source added: Think twice before injecting peptides bought online: unauthorized products can seriously harm you (Public advisory RA-81874) | — |
| Health Canada / Government of Canada |
| June 3, 2026 | Research | New research: Health Canada Public Advisory (RA-81874): Unauthorized Injectable Peptide Drugs Sold Online May Cause Serious Harm | BPC-157, TB-500, Retatrutide, CJC-1295, DSIP, Epitalon, GHK-Cu, Ipamorelin, KPV, Melanotan I/II, MOTS-C, NAD+, SS-31, HCG |
| Health Canada public advisory (RA-81874, published 2026-04-09) warning consumers about serious health risks of unauthorized injectable peptide drugs sold online and marketed for anti-aging, weight loss, bodybuilding, athletic performance, injury recovery, sleep, mental focus, or |
| June 3, 2026 | Source | New source added: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice | — |
| Nature (Springer Nature) |
| June 3, 2026 | Research | New research: Unimolecular Quintuple Agonist GLP-1–GIP–Lanifibranor Corrects Obesity and Diabetes in Mice (Nature, 2026) | GLP-1–GIP–lanifibranor, Semaglutide, Tirzepatide |
| Peer-reviewed preclinical study (Nature, published 29 April 2026; DOI 10.1038/s41586-026-10427-5; Helmholtz Munich with Indiana Biosciences Research Institute and the Novo Nordisk Research Center Indianapolis). Reports a unimolecular quintuple agonist, GLP-1–GIP–lanifibranor, a p |
| June 1, 2026 | Peptide | New peptide added: Bulevirtide | Bulevirtide |
| First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead). |
| May 29, 2026 | Peptide | New peptide added: Pegzilarginase-nbln | Pegzilarginase-nbln |
| PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026. |
| May 29, 2026 | Peptide | New peptide added: Navepegritide | Navepegritide |
| PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026. |
| May 29, 2026 | Peptide | New peptide added: Icotrokinra | Icotrokinra |
| Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis. |
| May 28, 2026 | FDA approval | New FDA-approved peptide: Metreleptin | Metreleptin |
| Myalept — Leptin deficiency in generalized lipodystrophy |
| May 28, 2026 | Peptide | New peptide added: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. |
| May 23, 2026 | Source | New source added: Self-reported side effects of semaglutide and tirzepatide in online communities | — |
| Nature Health (Springer Nature) |
| May 23, 2026 | Research | New research: Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities (Nature Health, 2026) | Semaglutide, Tirzepatide |
| Peer-reviewed pharmacovigilance study (Nature Health, 2026; DOI 10.1038/s44360-026-00108-y) applying large-scale natural-language analysis to 410,198 Reddit posts (May 2019-June 2025) mentioning semaglutide or tirzepatide. Of 67,008 users who self-reported use, 43.5% described at |
| May 22, 2026 | Source | New source added: FDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), First and Only Approved Treatment for Chronic HDV | — |
| Gilead Sciences, Inc. |
| May 22, 2026 | Source | New source added: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection | — |
| U.S. Food and Drug Administration |
| May 22, 2026 | Research | New research: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV): Hepcludex (Bulevirtide-gmod) | Bulevirtide |
| On May 22, 2026 the FDA granted accelerated approval to Hepcludex (bulevirtide-gmod), the first and only approved US treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Bulevirtide is an HBV/HDV entry inhibitor (N |
| May 22, 2026 | FDA approval | New FDA-approved peptide: Bulevirtide | Bulevirtide |
| Hepcludex — Chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Granted accelerated approval based on reduction in HDV RNA and ALT normalization (Phase 3 MYR301, Week 48); clinical-outcome benefit not yet established and contin |
| May 21, 2026 | Source | New source added: Lilly TRIUMPH-1 Phase 3 Press Release: Retatrutide Pivotal Obesity Trial | — |
| Eli Lilly and Company (investor.lilly.com) |
| May 21, 2026 | Source | New source added: Lilly TRIUMPH-1 Phase 3: Retatrutide 25% weight loss pivotal obesity trial May 2026 | — |
| Eli Lilly and Company / PRNewsWire |
| May 21, 2026 | Research | New research: Retatrutide TRIUMPH-1 Phase 3: 28.3% Weight Loss at 80 Weeks (Eli Lilly, May 2026) | Retatrutide, Tirzepatide, CagriSema |
| Phase 3 TRIUMPH-1 (Eli Lilly press release May 21, 2026): Retatrutide 12 mg produced 28.3% body weight loss (70.3 lb) over 80 weeks in adults with obesity without T2D. 9 mg: 25.9% (64.4 lb). 4 mg: 19.0% (47.2 lb). All doses met primary and key secondary endpoints. 45.3% of 12 mg |
| May 19, 2026 | Source | New source added: Safety Risks in the GLP-1 Market: An Update on Weight Loss Medication, May 2026 | — |
| Partnership for Safe Medicines |
| May 19, 2026 | Research | New research: Safety Risks in the GLP-1 Market: May 2026 Update on Compounded & Counterfeit Semaglutide/Tirzepatide | Semaglutide, Tirzepatide, Retatrutide |
| Partnership for Safe Medicines May 2026 roundup documenting safety risks across the GLP-1 weight-loss market: counterfeit Ozempic/Mounjaro seizures (US, Canada, Australia, India, UK), illicit online sales of unregistered semaglutide, tirzepatide and "research-use-only" retatrutid |
| May 18, 2026 | Source | New source added: FDA Warning Letter to 503B Facility Compounding Tirzepatide Post-Shortage | — |
| Partnership for Safe Medicines |
| May 18, 2026 | Research | New research: FDA Warns 503B Outsourcing Facility for Compounding Tirzepatide After Shortage Ended | Tirzepatide |
| FDA issued a warning to a 503B compounding pharmacy for producing tirzepatide after the official shortage ended, consistent with the agency's April 30, 2026 proposal to exclude GLP-1 drugs from the 503B bulks list. |
| May 4, 2026 | Source | New source added: FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs | — |
| Orrick, Herrington & Sutcliffe LLP |
| May 1, 2026 | Source | New source added: Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (doc 2026-08552) | — |
| U.S. Government Publishing Office / FDA |
| April 30, 2026 | Source | New source added: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List | — |
| U.S. Food and Drug Administration |
| April 30, 2026 | Research | New research: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List | Semaglutide, Tirzepatide, Liraglutide |
| FDA proposed (Apr 30, 2026; Federal Register May 1, 2026) to leave semaglutide, tirzepatide, and liraglutide OFF the 503B Bulk Drug Substances List, finding no clinical need for outsourcing-facility bulk compounding now that shortages have ended. Comment period closes June 29, 20 |
| April 22, 2026 | Source | New source added: FDA Pharmacy Compounding Advisory Committee Meeting July 23-24, 2026 | — |
| U.S. Food and Drug Administration |
| April 16, 2026 | Source | New source added: FDA's Pep(tide) Rally! What Compounders and Industry Need to Know | — |
| The FDA Law Blog |
| April 16, 2026 | Source | New source added: FDA Moves Toward Easing Restrictions on Certain Peptides | — |
| Fierce Pharma |
| April 16, 2026 | Source | New source added: FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List | — |
| Frier Levitt — FDA Healthcare Law |
| April 16, 2026 | Source | New source added: FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List | — |
| Orrick, Herrington & Sutcliffe LLP |
| April 16, 2026 | Research | New research: FDA Announces Removal of 12 Peptides from Category 2 — April 15, 2026 | BPC-157, TB-500, Semax, Epitalon, DSIP, GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-C, LL-37, DiHexa |
| On April 15, 2026, FDA announced removal of 12 peptide bulk drug substances from Category 2 effective April 22, 2026, following withdrawal of nominations. No longer "significant safety risk" designation but not yet on 503A Bulks List. PCAC reviews July 23-24, 2026. |
| April 15, 2026 | Source | New source added: FDA Announces Change in Status of 12 Peptides | — |
| SSRP Institute (Seeds Scientific Research & Performance) |
| April 15, 2026 | Source | New source added: FDA Federal Register Notice — Removal of 12 Peptides from Category 2 & PCAC Scheduling | — |
| U.S. Food and Drug Administration |
| April 1, 2026 | Research | New research: FDA Novel Drug Approval: Foundayo (Orforglipron) — First Oral GLP-1 Agonist | Orforglipron |
| FDA approved Foundayo (orforglipron) April 1, 2026. First oral GLP-1 receptor agonist for weight management in adults with obesity or overweight. Eli Lilly. |
| April 1, 2026 | FDA approval | New FDA-approved peptide: Orforglipron | Orforglipron |
| Foundayo — Obesity or overweight with at least one weight-related comorbidity in adults; combined with reduced-calorie diet and increased physical activity |
| March 19, 2026 | Source | New source added: Lilly TRANSCEND-T2D-1 Phase 3: Retatrutide HbA1c reduction in type 2 diabetes Mar 2026 | — |
| Eli Lilly and Company / PRNewsWire |
| March 17, 2026 | Research | New research: FDA Novel Drug Approval: Icotyde (Icotrokinra) — First Oral Peptide for Plaque Psoriasis | Icotrokinra |
| FDA approved Icotyde (icotrokinra) March 17, 2026. First-in-class oral macrocyclic peptide IL-23R antagonist for moderate-to-severe plaque psoriasis. J&J / Protagonist Therapeutics. |
| March 17, 2026 | FDA approval | New FDA-approved peptide: Icotrokinra | Icotrokinra |
| Icotyde — Moderate-to-severe plaque psoriasis in patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy |
| February 27, 2026 | Research | New research: FDA Novel Drug Approval: Yuviwel (Navepegritide) — CNP Analog for Achondroplasia | Navepegritide |
| FDA approved Yuviwel (navepegritide) Feb 27, 2026 for pediatric achondroplasia. PEGylated CNP analog activating NPR-B to promote bone growth. BioMarin. |
| February 27, 2026 | FDA approval | New FDA-approved peptide: Navepegritide | Navepegritide |
| Yuviwel — Increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses |
| February 23, 2026 | Research | New research: FDA Novel Drug Approval: Loargys (Pegzilarginase-nbln) — Enzyme for Arginase 1 Deficiency | Pegzilarginase-nbln |
| FDA approved Loargys (pegzilarginase-nbln) Feb 23, 2026. PEGylated arginase enzyme for Arginase 1 Deficiency. IV infusion with dietary protein restriction. |
| February 23, 2026 | FDA approval | New FDA-approved peptide: Pegzilarginase-nbln | Pegzilarginase-nbln |
| Loargys — Hyperarginemia in adults and pediatric patients 2 years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction |
| January 1, 2026 | Source | New source added: FDA Novel Drug Approvals for 2026 | — |
| U.S. Food and Drug Administration — Center for Drug Evaluation and Research |
| December 11, 2025 | Source | New source added: Lilly TRIUMPH-4 Phase 3: Retatrutide 28.7% weight loss + knee osteoarthritis Dec 2025 | — |
| Eli Lilly and Company / PRNewsWire |
| October 7, 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Connective tissue repair |
| October 7, 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Bone and cartilage healing |
| October 7, 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Bone remodeling support |
| October 7, 2025 | Peptide | New peptide added: Collagen Peptides | Collagen Peptides |
| Structural bone and joint support |
| October 7, 2025 | Peptide | New peptide added: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor |
| October 7, 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Cartilage and joint protection |
| October 7, 2025 | Peptide | New peptide added: Abaloparatide | Abaloparatide |
| Advanced bone anabolic |
| October 7, 2025 | Peptide | New peptide added: Teriparatide | Teriparatide |
| FDA-approved bone builder |
| October 7, 2025 | Peptide | New peptide added: Melanotan II | Melanotan II |
| Melanocortin system activator |
| October 7, 2025 | Peptide | New peptide added: Prostatilen | Prostatilen |
| Prostate and male hormone support |
| October 7, 2025 | Peptide | New peptide added: Thyreogen | Thyreogen |
| Thyroid function support |
| October 7, 2025 | Peptide | New peptide added: DHEA Peptide | DHEA Peptide |
| Hormone precursor support |
| October 7, 2025 | Peptide | New peptide added: Oxytocin | Oxytocin |
| Bonding and relaxation hormone |
| October 7, 2025 | Peptide | New peptide added: PT-141 | PT-141 |
| Sexual function peptide |
| October 7, 2025 | Peptide | New peptide added: HCG (Human Chorionic Gonadotropin) | HCG (Human Chorionic Gonadotropin) |
| Testosterone production support |
| October 7, 2025 | Peptide | New peptide added: Gonadorelin | Gonadorelin |
| GnRH for fertility |
| October 7, 2025 | Peptide | New peptide added: Kisspeptin | Kisspeptin |
| Reproductive hormone regulator |
| October 7, 2025 | Peptide | New peptide added: DSIP | DSIP |
| Pain perception modulation |
| October 7, 2025 | Peptide | New peptide added: Thymosin Beta-4 | Thymosin Beta-4 |
| Comprehensive tissue pain relief |
| October 7, 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Injury and inflammation pain relief |
| October 7, 2025 | Peptide | New peptide added: KPV | KPV |
| Anti-inflammatory pain relief |
| October 7, 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Multi-purpose healing for pain |
| October 7, 2025 | Peptide | New peptide added: LL-37 | LL-37 |
| Inflammatory pain modulation |
| October 7, 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Anti-inflammatory tissue repair |
| October 7, 2025 | Peptide | New peptide added: Actovegin | Actovegin |
| Hypoxic pain and healing |
| October 7, 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Joint and cartilage pain relief |
| October 7, 2025 | Peptide | New peptide added: Cerebrolysin | Cerebrolysin |
| Neuropathic pain support |
| October 7, 2025 | Peptide | New peptide added: PEA (Palmitoylethanolamide) | PEA (Palmitoylethanolamide) |
| Natural pain modulator |
| October 7, 2025 | Peptide | New peptide added: ARA-290 | ARA-290 |
| Neuropathic pain specialist |
| October 7, 2025 | Peptide | New peptide added: Epithalon | Epithalon |
| Circadian rhythm regulator |
| October 7, 2025 | Peptide | New peptide added: Semax Low Dose | Semax Low Dose |
| Evening cognitive calming |
| October 7, 2025 | Peptide | New peptide added: DSIP | DSIP |
| Delta sleep-inducing peptide |
| October 7, 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Recovery enhancement peptide |
| October 7, 2025 | Peptide | New peptide added: Cerebrolysin | Cerebrolysin |
| Neural restoration during sleep |
| October 7, 2025 | Peptide | New peptide added: Glycine Peptide | Glycine Peptide |
| Sleep quality amino peptide |
| October 7, 2025 | Peptide | New peptide added: Pinealon | Pinealon |
| Pineal gland bioregulator |
| October 7, 2025 | Peptide | New peptide added: Cortexin | Cortexin |
| Neuropeptide for rest |
| October 7, 2025 | Peptide | New peptide added: Melatonin Peptide Complex | Melatonin Peptide Complex |
| Enhanced melatonin delivery |
| October 7, 2025 | Peptide | New peptide added: Selank | Selank |
| Anxiolytic for sleep |
| October 7, 2025 | Peptide | New peptide added: KPV | KPV |
| Anti-inflammatory immune peptide |
| October 7, 2025 | Peptide | New peptide added: LL-37 | LL-37 |
| Antimicrobial defense peptide |
| October 7, 2025 | Peptide | New peptide added: AMP-K | AMP-K |
| Metabolic immune support |
| October 7, 2025 | Peptide | New peptide added: Splenopentin | Splenopentin |
| Spleen-derived immune peptide |
| October 7, 2025 | Peptide | New peptide added: Beta-Glucan Peptide | Beta-Glucan Peptide |
| Immune activating complex |
| October 7, 2025 | Peptide | New peptide added: Groprinosin | Groprinosin |
| Antiviral immune booster |
| October 7, 2025 | Peptide | New peptide added: Imunofan | Imunofan |
| Russian immune peptide |
| October 7, 2025 | Peptide | New peptide added: Vilon | Vilon |
| Simple immune dipeptide |
| October 7, 2025 | Peptide | New peptide added: Vladonix | Vladonix |
| Thymus bioregulator complex |
| October 7, 2025 | Peptide | New peptide added: Thymalin | Thymalin |
| Thymus restoration peptide |
| October 7, 2025 | Peptide | New peptide added: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Potent immune modulator |
| October 7, 2025 | Peptide | New peptide added: Copper Peptide GHK-Cu | Copper Peptide GHK-Cu |
| Multi-functional skin peptide |
| October 7, 2025 | Peptide | New peptide added: PT-141 (Bremelanotide) | PT-141 (Bremelanotide) |
| Libido enhancement peptide |
| October 7, 2025 | Peptide | New peptide added: Hexapeptide-11 | Hexapeptide-11 |
| Cell renewal peptide |
| October 7, 2025 | Peptide | New peptide added: Palmitoyl Tripeptide-5 | Palmitoyl Tripeptide-5 |
| Collagen booster |
| October 7, 2025 | Peptide | New peptide added: Snap-8 | Snap-8 |
| Enhanced Argireline |
| October 7, 2025 | Peptide | New peptide added: Syn-Coll | Syn-Coll |
| Collagen synthesis peptide |
| October 7, 2025 | Peptide | New peptide added: Matrixyl 3000 | Matrixyl 3000 |
| Advanced collagen booster |
| October 7, 2025 | Peptide | New peptide added: Argireline (Acetyl Hexapeptide-8) | Argireline (Acetyl Hexapeptide-8) |
| Botox-like peptide |
| October 7, 2025 | Peptide | New peptide added: Urolithin A | Urolithin A |
| Mitochondrial health compound |
| October 7, 2025 | Peptide | New peptide added: NMN | NMN |
| NAD+ precursor |
| October 7, 2025 | Peptide | New peptide added: Vladonix | Vladonix |
| Thymus bioregulator |
| October 7, 2025 | Peptide | New peptide added: Ovagen | Ovagen |
| Digestive system bioregulator |
| October 7, 2025 | Peptide | New peptide added: Prostatilen | Prostatilen |
| Prostate bioregulator |
| October 7, 2025 | Peptide | New peptide added: Thyreogen | Thyreogen |
| Thyroid bioregulator |
| October 7, 2025 | Peptide | New peptide added: Cortagen | Cortagen |
| Brain bioregulator |
| October 7, 2025 | Peptide | New peptide added: Vilon | Vilon |
| Thymus dipeptide |
| October 7, 2025 | Peptide | New peptide added: Thymalin | Thymalin |
| Thymus bioregulator |
| October 7, 2025 | Peptide | New peptide added: NA-Semax-Amidate | NA-Semax-Amidate |
| Triple modified Semax |
| October 7, 2025 | Peptide | New peptide added: Semax-Amidate | Semax-Amidate |
| Extended release Semax |
| October 7, 2025 | Peptide | New peptide added: Memantine | Memantine |
| NMDA antagonist |
| October 7, 2025 | Peptide | New peptide added: RG3 (Rhodiola) | RG3 (Rhodiola) |
| Adaptogenic peptide |
| October 7, 2025 | Peptide | New peptide added: FGL (Fibroblast Growth Loop) | FGL (Fibroblast Growth Loop) |
| NCAM mimetic |
| October 7, 2025 | Peptide | New peptide added: Cortexin | Cortexin |
| Neuropeptide complex |
| October 7, 2025 | Peptide | New peptide added: P21 (Adamax) | P21 (Adamax) |
| Neurogenic peptide |
| October 7, 2025 | Peptide | New peptide added: Selank-Amidate | Selank-Amidate |
| Extended release Selank |
| October 7, 2025 | Peptide | New peptide added: Epithalon + Follistatin Stack | Epithalon + Follistatin Stack |
| Anti-aging performance combo |
| October 7, 2025 | Peptide | New peptide added: HGH Fragment 176-191 | HGH Fragment 176-191 |
| Fat loss without GH effects |
| October 7, 2025 | Peptide | New peptide added: YK-11 | YK-11 |
| Myostatin inhibitor |
| October 7, 2025 | Peptide | New peptide added: ACE-031 | ACE-031 |
| Myostatin inhibitor |
| October 7, 2025 | Peptide | New peptide added: TB4-FRAG | TB4-FRAG |
| TB-500 fragment |
| October 7, 2025 | Peptide | New peptide added: GHRP-4 | GHRP-4 |
| Fourth generation GHRP |
| October 7, 2025 | Peptide | New peptide added: Tesamorelin | Tesamorelin |
| GHRH for visceral fat |
| October 7, 2025 | Peptide | New peptide added: Sermorelin | Sermorelin |
| GHRH for natural GH release |
| October 7, 2025 | Peptide | New peptide added: Orforglipron | Orforglipron |
| Oral GLP-1 |
| October 7, 2025 | Peptide | New peptide added: Liraglutide | Liraglutide |
| FDA-approved GLP-1 for weight loss |
| October 7, 2025 | Peptide | New peptide added: Retatrutide | Retatrutide |
| Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026. |
| October 7, 2025 | Peptide | New peptide added: Fragment 176-191 | Fragment 176-191 |
| HGH fragment for fat loss |
| October 7, 2025 | Peptide | New peptide added: Leptin | Leptin |
| Satiety hormone |
| October 7, 2025 | Peptide | New peptide added: Pramlintide | Pramlintide |
| Amylin analog for diabetes |
| October 7, 2025 | Peptide | New peptide added: CagriSema | CagriSema |
| Combination therapy |
| October 7, 2025 | Peptide | New peptide added: Dulaglutide | Dulaglutide |
| Weekly GLP-1 (Trulicity) |
| October 7, 2025 | Peptide | New peptide added: BPC-157 Stable | BPC-157 Stable |
| Stabilized BPC variant |
| October 7, 2025 | Peptide | New peptide added: FGL (Fibroblast Growth-Like) | FGL (Fibroblast Growth-Like) |
| Neural repair peptide |
| October 7, 2025 | Peptide | New peptide added: Actovegin | Actovegin |
| Tissue regeneration complex |
| October 7, 2025 | Peptide | New peptide added: Ghrelinomimetic | Ghrelinomimetic |
| Appetite and healing support |
| October 7, 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Joint and bladder support |
| October 7, 2025 | Peptide | New peptide added: Larazotide | Larazotide |
| Gut permeability regulator |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Pasireotide | Pasireotide |
| Signifor — Cushing's disease |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Lanreotide | Lanreotide |
| Somatuline — Acromegaly, neuroendocrine tumors |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Octreotide | Octreotide |
| Sandostatin — Acromegaly, carcinoid syndrome |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Desmopressin | Desmopressin |
| DDAVP, Stimate — Diabetes insipidus, hemophilia A |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Bivalirudin | Bivalirudin |
| Angiomax — Anticoagulation during cardiac procedures |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Pramlintide | Pramlintide |
| Symlin — Diabetes (adjunct to insulin) |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Abaloparatide | Abaloparatide |
| Tymlos — Postmenopausal osteoporosis |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Teriparatide | Teriparatide |
| Forteo — Osteoporosis |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Calcitonin | Calcitonin |
| Miacalcin, Fortical — Osteoporosis, Paget's disease |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Insulin | Insulin |
| Humalog, Novolog, Lantus, many others — Diabetes management |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Oxytocin | Oxytocin |
| Pitocin — Labor induction, postpartum bleeding |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Gonadorelin | Gonadorelin |
| Factrel — Hypogonadotropic hypogonadism |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Sermorelin | Sermorelin |
| Sermorelin Acetate — Growth hormone deficiency in children |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Tesamorelin | Tesamorelin |
| Egrifta — HIV-associated lipodystrophy |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Exenatide | Exenatide |
| Byetta, Bydureon — Type 2 diabetes |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Dulaglutide | Dulaglutide |
| Trulicity — Type 2 diabetes |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Liraglutide | Liraglutide |
| Victoza, Saxenda — Type 2 diabetes (Victoza), Weight management (Saxenda) |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Tirzepatide | Tirzepatide |
| Mounjaro, Zepbound — Type 2 diabetes (Mounjaro), Chronic weight management (Zepbound) |
| October 7, 2025 | FDA approval | New FDA-approved peptide: Semaglutide | Semaglutide |
| Ozempic, Wegovy, Rybelsus — Type 2 diabetes (Ozempic), Chronic weight management (Wegovy) |
| October 7, 2025 | Peptide | New peptide added: Dihexa | Dihexa |
| Potent cognitive enhancer |
| October 7, 2025 | Peptide | New peptide added: Epitalon | Epitalon |
| Longevity, telomere support |
| October 7, 2025 | Peptide | New peptide added: MOTS-c | MOTS-c |
| Mitochondrial optimization |
| October 7, 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Tissue repair, flexibility, inflammation |
| October 7, 2025 | Peptide | New peptide added: Melanotan II | Melanotan II |
| Tanning, libido |
| October 7, 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Healing & recovery, gut health |
| October 7, 2025 | Peptide | New peptide added: Copper Peptides | Copper Peptides |
| Skin regeneration |
| October 7, 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Skin health, anti-aging, wound healing |
| October 7, 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Wound healing, skin regeneration |
| October 7, 2025 | Peptide | New peptide added: Semax | Semax |
| Cognitive enhancement, focus, memory |
| October 7, 2025 | Peptide | New peptide added: Matrixyl (Palmitoyl Pentapeptide) | Matrixyl (Palmitoyl Pentapeptide) |
| Anti-aging skincare |
| October 7, 2025 | Peptide | New peptide added: Tirzepatide | Tirzepatide |
| Dual GIP/GLP-1 agonist for weight loss |
| October 7, 2025 | Peptide | New peptide added: Semaglutide | Semaglutide |
| Weight loss, blood sugar control |
| October 7, 2025 | Peptide | New peptide added: SS-31 (Elamipretide) | SS-31 (Elamipretide) |
| Mitochondrial optimization |
| October 7, 2025 | Peptide | New peptide added: Humanin | Humanin |
| Mitochondrial protection, longevity |
| October 7, 2025 | Peptide | New peptide added: Cerebrolysin | Cerebrolysin |
| Neuroprotection, recovery |
| October 7, 2025 | Peptide | New peptide added: NSI-189 | NSI-189 |
| Neurogenesis, depression |
| October 7, 2025 | Peptide | New peptide added: Selank | Selank |
| Anxiety reduction, focus |
| October 7, 2025 | Peptide | New peptide added: Hexarelin | Hexarelin |
| Potent GH releaser |
| October 7, 2025 | Peptide | New peptide added: MK-677 (Ibutamoren) | MK-677 (Ibutamoren) |
| Oral GH secretagogue |
| October 7, 2025 | Peptide | New peptide added: Ipamorelin | Ipamorelin |
| GH secretagogue, anti-aging |
| October 7, 2025 | Peptide | New peptide added: CJC-1295 | CJC-1295 |
| Growth hormone, muscle mass, fat loss |
| October 7, 2025 | Peptide | New peptide added: AOD-9604 | AOD-9604 |
| Fat loss, metabolic enhancement |
| October 7, 2025 | Peptide | New peptide added: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support |
| June 1, 2024 | Research | New research: Peptide Therapy in Sports Medicine: Current Evidence and Future Directions | BPC-157, TB-500, Ipamorelin, CJC-1295 |
| Critical review of peptide use in athletic recovery: available evidence, WADA prohibited status, ethical considerations. |
| May 1, 2024 | Source | New source added: Tirzepatide Prescribing Information (DailyMed SPL) | — |
| NLM / DailyMed |
| March 15, 2024 | Research | New research: Growth Hormone Secretagogues: Peptide and Non-Peptide Options in 2024 | Ipamorelin, CJC-1295, Sermorelin, MK-677 |
| Comprehensive comparison of GHRH analogs, GHRPs, and ghrelin mimetics for clinical and off-label applications. |
| February 1, 2024 | Research | New research: Oral Peptides and GLP-1 Analogs: Breaking the Injection Barrier | Orforglipron, Semaglutide (oral) |
| Review of advances in oral peptide bioavailability: Rybelsus SNAC technology, orforglipron, next-generation oral metabolic agents. |
| January 15, 2024 | Research | New research: BPC-157: A Comprehensive Overview of the Research Evidence | BPC-157 |
| Comprehensive review of BPC-157 preclinical evidence, proposed mechanisms, dosing, and limitations of available human data. |
| November 8, 2023 | Source | New source added: FDA Prescribing Information - Tirzepatide injection Zepbound 2023 | — |
| FDA / Eli Lilly |
| September 1, 2023 | Research | New research: The GLP-1 Revolution: How Semaglutide and Tirzepatide Are Reshaping Obesity Medicine | Semaglutide, Tirzepatide |
| Overview of GLP-1/GIP receptor agonist landscape, efficacy comparison, and future directions including oral formulations and triple agonists. |
| August 10, 2023 | Source | New source added: Retatrutide Phase 2 RCT - GIP/GLP-1/glucagon triple agonist (NEJM 2023) | — |
| New England Journal of Medicine |
| July 13, 2023 | Source | New source added: Orforglipron oral GLP-1 receptor agonist for obesity - Phase 2 | — |
| New England Journal of Medicine |
| June 1, 2023 | Research | New research: Russian Nootropic Peptides: Semax and Selank in Clinical Practice | Semax, Selank, NA-Semax-Amidate |
| Clinical review of Russian peptide nootropics: regulatory approval, mechanism, and comparative analysis. |
| May 1, 2023 | Research | New research: Melanocortin Peptides in Sexual Medicine: PT-141 and Melanotan II | PT-141, Melanotan II |
| Review of MC-receptor agonists for sexual dysfunction: PT-141 FDA approval for HSDD, off-label erectile use, Melanotan II safety concerns. |
| April 13, 2023 | Source | New source added: Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) | — |
| New England Journal of Medicine |
| January 1, 2023 | Source | New source added: FDA Prescribing Information - Semaglutide injection Wegovy 2023 | — |
| FDA / Novo Nordisk |
| September 1, 2022 | Source | New source added: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) | — |
| New England Journal of Medicine |
| September 1, 2022 | Research | New research: Mitochondrial Peptides and the Future of Aging Research | MOTS-c, Humanin, SS-31 |
| Comprehensive review of mitochondria-derived peptides as a new class of longevity therapeutics. |
| August 10, 2021 | Source | New source added: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) | — |
| New England Journal of Medicine |
| November 1, 2020 | Source | New source added: Thymosin alpha-1 reduces mortality of severe COVID-19 | — |
| International Journal of Infectious Diseases |
| January 1, 2020 | Source | New source added: FDA Prescribing Information - Teriparatide injection Forteo 2020 | — |
| FDA / Eli Lilly |
| January 1, 2020 | Source | New source added: Elamipretide SS-31 in Barth syndrome heart failure (PROGRESS) | — |
| JACC Heart Failure |
| June 21, 2019 | Source | New source added: FDA Prescribing Information - Bremelanotide injection Vyleesi 2019 | — |
| FDA / AMAG Pharmaceuticals |
| June 1, 2019 | Source | New source added: Bremelanotide PT-141 for HSDD in women - RECONNECT Phase 3 | — |
| Journal of Sexual Medicine |
| March 7, 2017 | Source | New source added: Abaloparatide for osteoporosis - ACTIVE trial | — |
| JAMA |
| November 10, 2016 | Source | New source added: Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6) | — |
| New England Journal of Medicine |
| April 1, 2016 | Source | New source added: Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease | — |
| Current Pharmaceutical Design |
| March 3, 2015 | Source | New source added: MOTS-c - mitochondrial-derived peptide regulating metabolism | — |
| Cell Metabolism |
| June 1, 2014 | Source | New source added: ARA-290 improves small fiber neuropathy in sarcoidosis - Phase 2 | — |
| Molecular Medicine |
| April 1, 2014 | Source | New source added: BPC-157 promotes tendon and ligament healing and accelerates recovery | — |
| Journal of Physiology and Pharmacology |
| February 1, 2014 | Source | New source added: GHK-Cu copper peptide and skin biology - comprehensive review | — |
| Journal of Aging Research and Clinical Practice |
| February 1, 2014 | Research | New research: GHK-Cu: More Than a Skin Peptide - Systemic Applications in Aging | Copper Peptide GHK-Cu |
| Expanding GHK-Cu beyond dermatology: gene expression modulation, anti-cancer effects, wound healing, systemic administration. |
| March 1, 2013 | Source | New source added: Thymosin alpha-1 for treatment of chronic hepatitis C | — |
| Hepatology |
| January 1, 2013 | Source | New source added: PEA palmitoylethanolamide for neuropathic pain - systematic review | — |
| Pain |
| January 1, 2013 | Source | New source added: Dihexa - orally active peptide with exceptional synaptic efficacy | — |
| Neuropsychopharmacology |
| January 1, 2013 | Research | New research: The Thymosin Family: Biological and Clinical Significance | Thymosin Alpha-1, Thymosin Beta-4 |
| Review of thymosin class peptides: alpha-1 immune modulation and clinical approvals, beta-4 tissue repair. |
| November 1, 2012 | Research | New research: Peptide Bioregulators: Khavinsons Life Work on Aging and Longevity | Epitalon, Thymalin, Vilon |
| Review of 40+ years of Khavinsons peptide bioregulators: mechanism, clinical applications, and longevity data. |
| August 1, 2012 | Source | New source added: Larazotide acetate reduces symptoms in celiac disease - Phase 2b | — |
| Gastroenterology |
| January 1, 2008 | Source | New source added: Thymosin Beta-4 and tissue repair - mechanisms and clinical applications | — |
| Annals of the New York Academy of Sciences |
| January 1, 2008 | Source | New source added: Selank - anxiolytic peptide with nootropic and immunomodulatory properties | — |
| Neurochemical Research |
| March 1, 2006 | Source | New source added: CJC-1295 long-acting GHRH analog - Phase 1 dose-escalation study | — |
| Journal of Clinical Endocrinology and Metabolism |
| December 1, 2003 | Source | New source added: Khavinson peptide bioregulators and aging | — |
| Annals of the New York Academy of Sciences |
| February 1, 2003 | Source | New source added: Semax and cognitive effects in patients with ischemic stroke | — |
| Cerebrovascular Disease |
| January 1, 2003 | Source | New source added: Epitalon tetrapeptide induces telomerase activity and telomere elongation | — |
| Bulletin of Experimental Biology and Medicine |
| November 1, 2001 | Source | New source added: Teriparatide for osteoporosis - randomised fracture prevention trial (NEJM 2001) | — |
| New England Journal of Medicine |
| September 1, 2001 | Source | New source added: Humanin - neuroprotective peptide derived from mitochondria | — |
| Nature Cell Biology |
| January 1, 1999 | Source | New source added: Growth hormone-releasing peptide ipamorelin - selectivity and safety | — |
| European Journal of Endocrinology |
| November 12, 1998 | Source | New source added: Effects of an oral ghrelin mimetic on body composition and outcomes (MK-677 NEJM 1998) | — |
| New England Journal of Medicine |